US20040138487A1 - Synthesis of non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation - Google Patents
Synthesis of non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation Download PDFInfo
- Publication number
- US20040138487A1 US20040138487A1 US10/741,117 US74111703A US2004138487A1 US 20040138487 A1 US20040138487 A1 US 20040138487A1 US 74111703 A US74111703 A US 74111703A US 2004138487 A1 US2004138487 A1 US 2004138487A1
- Authority
- US
- United States
- Prior art keywords
- butyl
- isopropyl
- diethylbutane
- dimethylpropane
- adamantyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003446 ligand Substances 0.000 title claims abstract description 73
- 239000003054 catalyst Substances 0.000 title claims description 14
- 238000003786 synthesis reaction Methods 0.000 title description 29
- 230000015572 biosynthetic process Effects 0.000 title description 28
- 238000009876 asymmetric hydrogenation reaction Methods 0.000 title description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 105
- 238000000034 method Methods 0.000 claims abstract description 36
- 230000009466 transformation Effects 0.000 claims abstract description 10
- SFRKSDZMZHIISH-UHFFFAOYSA-N 3-ethylhexane Chemical compound CCCC(CC)CC SFRKSDZMZHIISH-UHFFFAOYSA-N 0.000 claims description 98
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 claims description 78
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 54
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 53
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 49
- 125000004437 phosphorous atom Chemical group 0.000 claims description 47
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical group [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 claims description 31
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 30
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 claims description 28
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 22
- 229910000085 borane Inorganic materials 0.000 claims description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 16
- -1 nitro, amino, vinyl Chemical group 0.000 claims description 16
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 15
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims description 14
- 239000000758 substrate Substances 0.000 claims description 13
- 229910052723 transition metal Inorganic materials 0.000 claims description 13
- 150000003624 transition metals Chemical class 0.000 claims description 13
- 125000004429 atom Chemical group 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 claims description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 claims description 8
- 239000010948 rhodium Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 229910052768 actinide Inorganic materials 0.000 claims description 7
- 150000001255 actinides Chemical class 0.000 claims description 7
- 229910052747 lanthanoid Inorganic materials 0.000 claims description 7
- 150000002602 lanthanoids Chemical class 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 229910052703 rhodium Inorganic materials 0.000 claims description 7
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical group [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 claims description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- 238000005984 hydrogenation reaction Methods 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 239000012280 lithium aluminium hydride Substances 0.000 claims description 5
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 claims description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 5
- 229910001914 chlorine tetroxide Inorganic materials 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Chemical compound [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 claims description 4
- 239000012279 sodium borohydride Substances 0.000 claims description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 125000004104 aryloxy group Chemical group 0.000 claims description 3
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 claims description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 3
- 229920002554 vinyl polymer Polymers 0.000 claims description 3
- OYVOPWAGYAKJAZ-UHFFFAOYSA-N 2-(chloromethyl)-1-[2-(chloromethyl)naphthalen-1-yl]naphthalene Chemical group C1=CC=C2C(C3=C4C=CC=CC4=CC=C3CCl)=C(CCl)C=CC2=C1 OYVOPWAGYAKJAZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 150000001733 carboxylic acid esters Chemical class 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 150000002825 nitriles Chemical class 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 229910052763 palladium Inorganic materials 0.000 claims description 2
- IQVGRXFIVHSDFL-UHFFFAOYSA-N (2-bromophenyl)phosphane Chemical compound PC1=CC=CC=C1Br IQVGRXFIVHSDFL-UHFFFAOYSA-N 0.000 claims 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 3
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 claims 3
- MBTZESLSLVNAAJ-UHFFFAOYSA-N (2-bromophenyl)-methyl-[[1-(2-methylnaphthalen-1-yl)naphthalen-2-yl]methyl]phosphane Chemical compound C=1C=C2C=CC=CC2=C(C=2C3=CC=CC=C3C=CC=2C)C=1CP(C)C1=CC=CC=C1Br MBTZESLSLVNAAJ-UHFFFAOYSA-N 0.000 claims 2
- VAEMTXXZNPDQNC-UHFFFAOYSA-N 1-bromo-2-diethoxyphosphorylbenzene Chemical compound CCOP(=O)(OCC)C1=CC=CC=C1Br VAEMTXXZNPDQNC-UHFFFAOYSA-N 0.000 claims 2
- WQONPSCCEXUXTQ-UHFFFAOYSA-N 1,2-dibromobenzene Chemical compound BrC1=CC=CC=C1Br WQONPSCCEXUXTQ-UHFFFAOYSA-N 0.000 claims 1
- HZHBIPCFTRPWKY-UHFFFAOYSA-N 3-cyano-5-methylhex-3-enoic acid Chemical group CC(C)C=C(C#N)CC(O)=O HZHBIPCFTRPWKY-UHFFFAOYSA-N 0.000 claims 1
- 206010034962 Photopsia Diseases 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- MJUJXFBTEFXVKU-UHFFFAOYSA-N diethyl phosphonate Chemical compound CCOP(=O)OCC MJUJXFBTEFXVKU-UHFFFAOYSA-N 0.000 claims 1
- 229910000065 phosphene Inorganic materials 0.000 claims 1
- 229940086542 triethylamine Drugs 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 36
- 229910052751 metal Inorganic materials 0.000 abstract description 16
- 239000002184 metal Substances 0.000 abstract description 15
- 238000002360 preparation method Methods 0.000 abstract description 2
- 0 *P(*)C Chemical compound *P(*)C 0.000 description 68
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 46
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 44
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 34
- 239000000243 solution Substances 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- 235000019439 ethyl acetate Nutrition 0.000 description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- 238000006555 catalytic reaction Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000004679 31P NMR spectroscopy Methods 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 229940098779 methanesulfonic acid Drugs 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000000844 transformation Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- JPINHYFOWCBINQ-UHFFFAOYSA-N B.CC(C)(C)PC(C)(C)C Chemical compound B.CC(C)(C)PC(C)(C)C JPINHYFOWCBINQ-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 4
- 125000005610 enamide group Chemical group 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- CQRPUKWAZPZXTO-UHFFFAOYSA-M magnesium;2-methylpropane;chloride Chemical compound [Mg+2].[Cl-].C[C-](C)C CQRPUKWAZPZXTO-UHFFFAOYSA-M 0.000 description 4
- GWLJTAJEHRYMCA-UHFFFAOYSA-N phospholane Chemical compound C1CCPC1 GWLJTAJEHRYMCA-UHFFFAOYSA-N 0.000 description 4
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000003039 volatile agent Substances 0.000 description 4
- DVPUBLCBQBQPOU-JTQLQIEISA-N (4s)-4-benzyl-3-(2-chloroacetyl)-1,3-oxazolidin-2-one Chemical compound C1OC(=O)N(C(=O)CCl)[C@H]1CC1=CC=CC=C1 DVPUBLCBQBQPOU-JTQLQIEISA-N 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LJPFWCBUSPMLGW-UHFFFAOYSA-N B.CPC(C)(C)C Chemical compound B.CPC(C)(C)C LJPFWCBUSPMLGW-UHFFFAOYSA-N 0.000 description 3
- OEEZDMJGTWGNQA-UHFFFAOYSA-N C1=CC2C=CC1C2.[CH2-][C+2]([CH2-])(CC)CC Chemical compound C1=CC2C=CC1C2.[CH2-][C+2]([CH2-])(CC)CC OEEZDMJGTWGNQA-UHFFFAOYSA-N 0.000 description 3
- LVOHZKHAUFOPSZ-UHFFFAOYSA-N CC.CC1=C(C)C=CC=C1 Chemical compound CC.CC1=C(C)C=CC=C1 LVOHZKHAUFOPSZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000004296 chiral HPLC Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N CCCCC Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- UORVGPXVDQYIDP-BJUDXGSMSA-N borane Chemical group [10BH3] UORVGPXVDQYIDP-BJUDXGSMSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- CDPKWOKGVUHZFR-UHFFFAOYSA-N dichloro(methyl)phosphane Chemical compound CP(Cl)Cl CDPKWOKGVUHZFR-UHFFFAOYSA-N 0.000 description 2
- VURFVHCLMJOLKN-UHFFFAOYSA-N diphosphane Chemical compound PP VURFVHCLMJOLKN-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 2
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 2
- 238000001394 phosphorus-31 nuclear magnetic resonance spectrum Methods 0.000 description 2
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- SLRCCWJSBJZJBV-AJNGGQMLSA-N sparteine Chemical compound C1N2CCCC[C@H]2[C@@H]2CN3CCCC[C@H]3[C@H]1C2 SLRCCWJSBJZJBV-AJNGGQMLSA-N 0.000 description 2
- 229960001945 sparteine Drugs 0.000 description 2
- 150000003900 succinic acid esters Chemical class 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VVZLRWNOZJKUOQ-UHFFFAOYSA-N 2-[tert-butyl(methyl)phosphanyl]ethanol Chemical compound CC(C)(C)P(C)CCO VVZLRWNOZJKUOQ-UHFFFAOYSA-N 0.000 description 1
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 description 1
- BJPSBLPAWZBSOG-UHFFFAOYSA-N B[PH](C)(C)C(C)(C)C.B[PH](C)(CC[PH](B)(C)C(C)(C)C)C(C)(C)C.C=C(N=[Ac])C(=O)OC.COC(=O)C(C)N=[Ac] Chemical compound B[PH](C)(C)C(C)(C)C.B[PH](C)(CC[PH](B)(C)C(C)(C)C)C(C)(C)C.C=C(N=[Ac])C(=O)OC.COC(=O)C(C)N=[Ac] BJPSBLPAWZBSOG-UHFFFAOYSA-N 0.000 description 1
- HFYNOKLBCQBJBY-UHFFFAOYSA-N B[PH](C)(CC[PH](B)(C(C)(C)C)C(C)(C)C)C(C)(C)C.CC(C)(C)[PH](C)(C)CC[PH](C)(C(C)(C)C)C(C)(C)C Chemical compound B[PH](C)(CC[PH](B)(C(C)(C)C)C(C)(C)C)C(C)(C)C.CC(C)(C)[PH](C)(C)CC[PH](C)(C(C)(C)C)C(C)(C)C HFYNOKLBCQBJBY-UHFFFAOYSA-N 0.000 description 1
- OGTKOCXULYKHJL-UHFFFAOYSA-N B[PH](C)(CC[PH](B)(C)C(C)(C)C)C(C)(C)C Chemical compound B[PH](C)(CC[PH](B)(C)C(C)(C)C)C(C)(C)C OGTKOCXULYKHJL-UHFFFAOYSA-N 0.000 description 1
- FBKDXQAEEKLTKS-UHFFFAOYSA-N B[PH]1(C)CC2=C(C3=C(C=CC=C3)C=C2)C2=C(C=CC3=C2C=CC=C3)C1 Chemical compound B[PH]1(C)CC2=C(C3=C(C=CC=C3)C=C2)C2=C(C=CC3=C2C=CC=C3)C1 FBKDXQAEEKLTKS-UHFFFAOYSA-N 0.000 description 1
- ZGYDFYYYMLRXJZ-UHFFFAOYSA-N C(C1CCC1)c1ccccc1C1CCCC1 Chemical compound C(C1CCC1)c1ccccc1C1CCCC1 ZGYDFYYYMLRXJZ-UHFFFAOYSA-N 0.000 description 1
- KKUDPSPWRDRENH-UHFFFAOYSA-N C.[H][PH](B)(C)C(C)(C)C Chemical compound C.[H][PH](B)(C)C(C)(C)C KKUDPSPWRDRENH-UHFFFAOYSA-N 0.000 description 1
- 229930008564 C01BA04 - Sparteine Natural products 0.000 description 1
- LXWHXJGDAAGYIF-UHFFFAOYSA-M C1=CC2C=CC1C2.FB(F)F.[CH2][Rh+]([CH2])(CC)CC.[F-] Chemical compound C1=CC2C=CC1C2.FB(F)F.[CH2][Rh+]([CH2])(CC)CC.[F-] LXWHXJGDAAGYIF-UHFFFAOYSA-M 0.000 description 1
- GXBCZVNLGPEKOJ-UHFFFAOYSA-N CC(C)(C)[P@H]1(C)CC[P@@H](C)(C(C)(C)C)[Rh]1 Chemical compound CC(C)(C)[P@H]1(C)CC[P@@H](C)(C(C)(C)C)[Rh]1 GXBCZVNLGPEKOJ-UHFFFAOYSA-N 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229910004039 HBF4 Inorganic materials 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- XGPWKZSHGVTERU-UHFFFAOYSA-N [tert-butyl(methyl)boranyl]phosphane Chemical compound CB(P)C(C)(C)C XGPWKZSHGVTERU-UHFFFAOYSA-N 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical group 0.000 description 1
- 238000005865 alkene metathesis reaction Methods 0.000 description 1
- SLRCCWJSBJZJBV-UHFFFAOYSA-N alpha-isosparteine Natural products C1N2CCCCC2C2CN3CCCCC3C1C2 SLRCCWJSBJZJBV-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- NFTWUNMDOWXENK-UHFFFAOYSA-N boron;ditert-butylphosphane Chemical compound [B].CC(C)(C)PC(C)(C)C NFTWUNMDOWXENK-UHFFFAOYSA-N 0.000 description 1
- BWJRMVLPCQPWGR-UHFFFAOYSA-N boron;phosphane Chemical compound [B].P BWJRMVLPCQPWGR-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940125890 compound Ia Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000011982 enantioselective catalyst Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000005669 hydrocyanation reaction Methods 0.000 description 1
- 238000007037 hydroformylation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000006459 hydrosilylation reaction Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- XOPUORAQCYGJPT-UHFFFAOYSA-N methanesulfonic acid;hydrochloride Chemical compound Cl.CS(O)(=O)=O XOPUORAQCYGJPT-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- SJYNFBVQFBRSIB-UHFFFAOYSA-N norbornadiene Chemical compound C1=CC2C=CC1C2 SJYNFBVQFBRSIB-UHFFFAOYSA-N 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- WJIBZZVTNMAURL-UHFFFAOYSA-N phosphane;rhodium Chemical class P.[Rh] WJIBZZVTNMAURL-UHFFFAOYSA-N 0.000 description 1
- 150000004850 phospholanes Chemical class 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- ZBTYGZQHPMJJFS-UHFFFAOYSA-N tert-butyl(dimethyl)phosphane Chemical compound CP(C)C(C)(C)C ZBTYGZQHPMJJFS-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/22—Organic complexes
- B01J31/2282—Unsaturated compounds used as ligands
- B01J31/2295—Cyclic compounds, e.g. cyclopentadienyls
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
- B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
- B01J31/2409—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
- B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
- B01J31/2409—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom
- B01J31/2414—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom comprising aliphatic or saturated rings
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
- B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
- B01J31/2419—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising P as ring member
- B01J31/2428—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising P as ring member with more than one complexing phosphine-P atom
- B01J31/2433—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising P as ring member with more than one complexing phosphine-P atom comprising aliphatic or saturated rings
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
- B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
- B01J31/2442—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems
- B01J31/2447—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems and phosphine-P atoms as substituents on a ring of the condensed system or on a further attached ring
- B01J31/2452—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems and phosphine-P atoms as substituents on a ring of the condensed system or on a further attached ring with more than one complexing phosphine-P atom
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
- B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
- B01J31/2442—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems
- B01J31/2447—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems and phosphine-P atoms as substituents on a ring of the condensed system or on a further attached ring
- B01J31/2452—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems and phosphine-P atoms as substituents on a ring of the condensed system or on a further attached ring with more than one complexing phosphine-P atom
- B01J31/2457—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems and phosphine-P atoms as substituents on a ring of the condensed system or on a further attached ring with more than one complexing phosphine-P atom comprising aliphatic or saturated rings, e.g. Xantphos
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
- B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
- B01J31/2442—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems
- B01J31/2461—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems and phosphine-P atoms as ring members in the condensed ring system or in a further ring
- B01J31/2471—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems and phosphine-P atoms as ring members in the condensed ring system or in a further ring with more than one complexing phosphine-P atom
- B01J31/2476—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems and phosphine-P atoms as ring members in the condensed ring system or in a further ring with more than one complexing phosphine-P atom comprising aliphatic or saturated rings
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
- B01J31/2404—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
- B01J31/2442—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems
- B01J31/2461—Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring comprising condensed ring systems and phosphine-P atoms as ring members in the condensed ring system or in a further ring
- B01J31/248—Bridged ring systems, e.g. 9-phosphabicyclononane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B53/00—Asymmetric syntheses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0073—Rhodium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/5027—Polyphosphines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/50—Organo-phosphines
- C07F9/5045—Complexes or chelates of phosphines with metallic compounds or metals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/653—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6568—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
- C07F9/65683—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms the ring phosphorus atom being part of a phosphine
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
- B01J2231/60—Reduction reactions, e.g. hydrogenation
- B01J2231/64—Reductions in general of organic substrates, e.g. hydride reductions or hydrogenations
- B01J2231/641—Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
- B01J2231/60—Reduction reactions, e.g. hydrogenation
- B01J2231/64—Reductions in general of organic substrates, e.g. hydride reductions or hydrogenations
- B01J2231/641—Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes
- B01J2231/645—Hydrogenation of organic substrates, i.e. H2 or H-transfer hydrogenations, e.g. Fischer-Tropsch processes of C=C or C-C triple bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/02—Compositional aspects of complexes used, e.g. polynuclearity
- B01J2531/0261—Complexes comprising ligands with non-tetrahedral chirality
- B01J2531/0266—Axially chiral or atropisomeric ligands, e.g. bulky biaryls such as donor-substituted binaphthalenes, e.g. "BINAP" or "BINOL"
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/80—Complexes comprising metals of Group VIII as the central metal
- B01J2531/82—Metals of the platinum group
- B01J2531/822—Rhodium
Definitions
- This invention relates to non-C 2 -symmetric bisphosphine (BisP) ligands and a method for their preparation.
- this invention relates to forming metal/bisphosphine complexes that catalyze asymmetric transformation reactions to generate high enantiomeric excesses of formed compounds.
- the invention also relates to a method for preparing BisP.
- a growing trend in the pharmaceutical industry is to market chiral drugs in enantiomerically pure form to provide desired positive effects in humans.
- Production of enantiomerically pure compounds is important for several reasons.
- one enantiomer often provides a desired biological function through interactions with natural binding sites, but another enantiomer typically does not have the same function or effect. Further, it is possible that one enantiomer has harmful side effects, while another enantiomer provides a desired positive biological activity.
- Asymmetric catalysis is often the most efficient method for the synthesis of enantiomerically enriched compounds because a small amount of a chiral catalyst can be used to produce a large quantity of a chiral target molecule.
- asymmetric catalysis As the key step in the production of enantiomerically pure compounds with a tremendous effort focused on developing new asymmetric catalysts for these reactions (Morrison J. D., ed. Asymmetric Synthesis , New York: Academic Press, 1985:5; Bosnich B., ed. Asymmetric Catalysis , Dordrecht, Netherlands: Martinus Nijhoff Publishers, 1986; Brunner H.
- BPE, Duphos, and BisP ligands are some of the most efficient and broadly useful ligands developed for asymmetric hydrogenation to date (Burk M. J. Chemtracts 1998; 11(11):787-802 (CODEN: CHEMFW ISSN: 1431-9268. CAN 130:38423; AN 1998:698087 CAPLUS); Burk M. J., Bienewald F., Harris M., Zanotti-Gerosa A. Angew Chew., Int. Ed. 1998;37(13/14):1931-1933; Burk, M. J., Casy G., Johnson N. B. J. Org. Chem.
- a Rhodium/Duphos complex can be used to selectively form (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid, known as pregabalin, which is used as an anti-seizure drug.
- S-enantiomer which is produced in an enantiomeric excess, is preferred because it shows better anticonvulsant activity than the R-enantiomer (Yuen et al., Bioorganic & Medicinal Chemistry Letters 1994;4:823).
- BPE, Duphos, and BisP have shown high enantioselectivities in numerous asymmetric reactions. Improved reaction of BPE, Duphos, and BisP is attributed to, among other factors, rigidity in their C 2 -symmetric structure. If the spatial area of a metal/phosphine ligand structure, such as BisP, is divided into four quadrants, as shown in Scheme 1, alternating hindered and unhindered quadrants are formed.
- multiple chiral centers in these ligands increases the difficulty in synthesis of these compounds. Further, the multiple chiral centers could increase the cost associated with forming the ligands.
- C 2 -symmetric bisphosphines such as BisP
- Scheme 2 Imamoto, T., Watanabe J., Wada Y., Masuda H., Yamada H., Tsuruta H., Matsukawa S., Yamaguchi K. J. Am. Chem. Soc. 1998;120(7):1635-1636).
- a proton from one of the methyl groups of t-butyldimethyl phosphine is selectively deprotonated with a chiral base, such as s-BuLi and ( ⁇ )-sparteine, and then the resulting anion couples with itself in the presence of copper(II) chloride to provide the bisphosphine borane protected ligand, in about 40% yield and >99% enantiomeric excess after recrystallization.
- the rhodium complex of BisP is known to give high enantiomeric excess in hydrogenation reactions for a variety of substrates. For instance, the rhodium-BisP catalyst hydrogenates ⁇ -N-acetylmethylacrylate to produce 98% enantiomeric excess (Imamoto T. et al., supra., 1998).
- a drawback to the synthesis of the BisP ligand in Scheme 2 is that only one antipode of sparteine is available in nature, and therefore, only one enantiomer of the ligand (the S,S isomer) can be synthesized via this route.
- Ligand and metal/ligand complexes are needed that can further improve the production of enantiomerically active forms of compounds.
- Non-C 2 -symmetric bisphosphine ligands when complexed with a metal, serve as catalysts in asymmetric hydrogenation reactions to form enantiomerically enriched compounds.
- One non-C 2 -symmetric bisphosphine is represented by the general Formula I:
- the achiral phosphorous group includes at least one achiral phosphorous atom having one bond to each of two identical atoms other than the bridge;
- the chiral phosphorous group comprises at least one phosphorous atom, wherein the at least one phosphorous atom is chiral or the at least one phosphorous atom is bonded to a chiral substituent;
- the Bridge is a —(CH 2 ) n — where n is an integer from 1 to 12; a 1,2-divalent phenyl; or a 1,2-divalent substituted phenyl.
- Another non-C 2 -symmetric bisphosphine compound of present invention has the general Formula II:
- the achiral phosphorous group includes at least one achiral phosphorous atom having one bond to each of two identical atoms other than the bridge;
- the chiral phosphorous group comprises at least one phosphorous atom, wherein the at least one phosphorous atom is chiral or the at least one phosphorous atom is bonded to a chiral substituent;
- each Y is independently halogen, alkyl, alkoxy, aryl, aryloxy, nitro, amino, vinyl, substituted vinyl, alkynyl, or sulfonic acid, and n is an integer from 0 to 4 equal to the number of unsubstituted aromatic ring carbons.
- Another aspect of the invention is directed to the method for forming P-chiral bisphosphine ligands.
- Compounds used as synthons during the synthesis of non-C 2 -symmetric bisphosphine ligands include compounds with the Formulas III, IV, V, and VI:
- R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane) c-C 5 H 9 , or c-C 6 H 11 ; and Ms is mesylate.
- Another aspect of the invention is directed to methods for forming non-C 2 -bisphosphine ligands.
- the methods include preparing compounds of the general structural Formulas I and II, as shown in Schemes 4-12.
- Another compound of the present invention has the general Formula VIII:
- the achiral phosphorous group includes at least one achiral phosphorous atom having one bond to each of two identical atoms other than the bridge;
- the chiral phosphorous group comprises at least one phosphorous atom, wherein the at least one phosphorous atom is chiral or the at least one phosphorous atom is bonded to a chiral substituent;
- a Bridge is a —(CH 2 ) n — where n is an integer from 1 to 12; a 1,2-divalent phenyl; or a 1,2-divalent substituted phenyl;
- M is a transition metal, an actinide, or a lanthanide
- Z is BF 4 , PF 6 , SbF 6 , OTf, or ClO 4 .
- Yet another aspect of the invention is directed to forming enantiomeric excesses of compounds catalyzed with the metal/non-C 2 -symmetric bisphosphine complexes in asymmetric reactions.
- the present invention is applicable to the synthesis of non-Co-symmetric bisphosphine ligands for use in metal/non-C 2 -symmetric bisphosphine complexes for asymmetric catalysis.
- the present invention is directed to reacting the metal/non-C 2 -symmetric bisphosphine complexes to produce enantiomeric excesses of compound in asymmetric hydrogenation syntheses. While the present invention is not so limited, an appreciation of various aspects of the invention will be gained through a discussion of the examples provided below.
- the “corresponding enantiomer” means that if a compound includes a stereochemical configuration designated as R, the corresponding enantiomer is the S configuration. If a compound has an S configuration, the corresponding enantiomer is the R configuration. If a compound has a stereochemical configuration of 1R,2S, the “corresponding enantiomer” is the 1S,2R compound. Similarly, if a compound has an 1S,2R configuration, the “corresponding enantiomer” is the 1R,2S compound. If a P-chiral compound has an 1S,2S configuration, the “corresponding enantiomer” is the 1R,2R compound. If a compound has an 1R,2R configuration, the “corresponding enantiomer” is the 1S,2S compound.
- a high level of enantioselectivity means a hydrogenation that yields a product of greater than or equal to about 80%, preferably, greater than or equal to about 90% enantiomeric excess (abbreviated e.e.).
- Enantiomeric excess is defined as the ratio (% R ⁇ % S)/(% R+% S) ⁇ 100, where % R is the percentage of R enantiomer and % S is the percentage of S enantiomer in a sample of optically active compound.
- % R is the percentage of R enantiomer
- % S is the percentage of S enantiomer in a sample of optically active compound.
- a “compound with a high degree of enantiomeric purity,” or a “compound of high enantiomeric purity” is meant a compound that exhibits enantiomeric excess to the extent of greater than or equal to about 90%, preferably, greater than or equal to about 95% enantiomeric excess (abbreviated e.e.).
- the present invention provides novel non-C 2 -symmetric bisphosphine substituted compounds of the general Formula I:
- the achiral phosphorous group includes at least one achiral phosphorous atom having one bond to each of two identical atoms other than the bridge;
- the chiral phosphorous group comprises at least one phosphorous atom, wherein the at least one phosphorous atom is chiral or the at least one phosphorous atom is bonded to a chiral substituent;
- the Bridge is a —(CH 2 ) n — where n is an integer from 1 to 12; a 1,2-divalent phenyl; or a 1,2-divalent substituted phenyl.
- Another non-C 2 -symmetric bisphosphine compound of present invention has the general Formula II:
- the achiral phosphorous group includes at least one achiral phosphorous atom having one bond to each of two identical atoms other than the bridge;
- the chiral phosphorous group comprises at least one phosphorous atom, wherein the at least one phosphorous atom is chiral or the at least one phosphorous atom is bonded to a chiral substituent;
- each Y is independently halogen, alkyl, alkoxy, aryl, aryloxy, nitro, amino, vinyl, substituted vinyl, alkynyl, or sulfonic acid, and n is an integer from 0 to 4 equal to the number of unsubstituted aromatic ring carbons.
- alkyl includes a straight or branched saturated aliphatic hydrocarbon chain, such as, for example, methyl, ethyl, propyl, isopropyl (1-methylethyl), butyl, tert-butyl (1,1-dimethylethyl), and the like.
- aryl group includes an aromatic hydrocarbon group, including fused aromatic rings, such as, for example phenyl and naphthyl. Such groups may be unsubstituted or substituted on the aromatic ring by, for example, an alkoxy group of 1 to 4 carbon atoms, an amino group, a hydroxy group, or an acetyloxy group.
- aralkyl group includes an aromatic hydrocarbon group, including fused aromatic rings, such as for example, phenyl and naphthyl, bonded to an alkyl group with the alkyl bonded to the phospholane ring.
- the aromatic hydrocarbon group may be unsubstituted or substituted (ring substituted aralkyl) by, for example, an alkoxy group of 1 to 4 carbon atoms, an amino group, a hydroxy group, or an acetyloxy group.
- LAH lithium aluminum hydride
- Achiral phosphorous groups include, but are not limited to, the following:
- R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C 5 H 9 , or c-C 6 H 11 .
- Chiral phosphorous groups include, but are not limited to, the following and their corresponding enantiomers:
- R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C 5 H 9 , or C—C 6 H 11 ;
- R 2 is methyl, ethyl, isopropyl, cyclohexyl, benzyl, a ring substituted benzyl, an aryl, or a ring substituted aryl;
- R 3 is OBn, OH, sulphonate, or hydrogen.
- a preferred R group for the achiral phosphorous groups of compounds of the general Formula I is t-butyl.
- examples of other preferred non-C 2 -symmetric bisphosphine ligands of the general Formula I include, but are not limited to, those compounds in which R is isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C 5 H 9 , or c-C 6 H 11 and their corresponding enantiomers.
- R is t-butyl.
- R is isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C 5 H 9 , or c-C 6 H 11 .
- R is t-butyl
- R is t-butyl, and R 2 is alkyl.
- the non-C 2 -symmetric bisphosphine substituted compound, 1-((R)-2-tert-butyl-methyl-phosphanyl)-2-((R,R)-2,5-dialkylphosphanyl) benzene is represented by the Formula IIa:
- R is t-butyl, and R 2 is alkyl.
- Compounds of the general Formulas Ia, Ib, and Ic include the corresponding enantiomer of the compound shown in the structural formulas.
- the bisphosphine compounds of Formula I and II of the present invention are useful as transition metal ligands in asymmetric catalysis.
- the use of these ligands to form transition metal catalysts results in a high level of enantioselective and stereochemical control in the catalyzed hydrogenation of unsaturated substrates.
- Compounds I and II include one to three chiral centers instead of the four chiral centers that are found in molecules such as Duphos.
- Ligands displaying the structural motif of Ia do not necessarily have to contain bulky groups on phosphorous that are the same. In other words, as long as there are three sterically hindered quadrants in the metal-ligand complex, the desired effect in asymmetric transformations will be achieved.
- R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C 5 H 9 , or c-C 6 H 11 ; and Ms is mesylate.
- the above bisphospholane compounds of Formulas I, II, and their corresponding enantiomers can be complexed with any of the transition metals as well as the lanthanides and actinides. Such complexes are formed by methods known in the art.
- Another compound of the present invention includes the metal/P-chiral phospholane complex with the general structural Formula VIII and its corresponding enantiomer:
- the achiral phosphorous group includes at least one achiral phosphorous atom having one bond to each of two identical atoms other than the bridge;
- the chiral phosphorous group comprises at least one phosphorous atom, wherein the at least one phosphorous atom is chiral or the at least one phosphorous atom is bonded to a chiral substituent;
- a Bridge is a —(CH 2 ) n — where n is an integer from 1 to 12; a 1,2-divalent phenyl; or a 1,2-divalent substituted phenyl;
- M is a transition metal, an actinide, or a lanthanide
- Z is BF 4 , PF 6 , SbF 6 , OTf, or ClO 4 .
- Preferred transition metal complexes of the present invention are those including the above described preferred compounds complexed with rhodium.
- the synthesis the non-C 2 borane-protected ligands can be formed through synthons that are formed as shown in Scheme 3.
- R is t-butyl, isopropyl, adamantyl, (1,1)-dimethylpropane, (1,1-diethylbutane), c-C 5 H 9 , or c-C 6 H 11 ; and Ms is mesylate.
- R is t-butyl, isopropyl, adamantyl, (1,1)-dimethylpropane, (1,1-diethylbutane), c-C 5 H 9 , or c-C 6 H 11 .
- the above synthons can be used in a variety of reactions to form non-C 2 -symmetric ligands as shown in Schemes 4-8.
- R is t-butyl, isopropyl, adamantyl, (1,1)-dimethylpropane, (1,1-diethylbutane), c-C 5 H 9 , or c-C 6 H 11 ; and Ms is mesylate.
- R is t-butyl, isopropyl, adamantyl, (1,1)-dimethylpropane, (1,1-diethylbutane), c-C 5 H 9 , or c-C 6 H 11 ; and Ms is mesylate.
- R is t-butyl, isopropyl, adamantyl, (1,1)-dimethylpropane, (1,1-diethylbutane), c-C 5 H 9 , or c-C 6 H 11 ; and Ms is mesylate.
- R is t-butyl, isopropyl, adamantyl, (1,1)-dimethylpropane, (1,1-diethylbutane), c-C 5 H 9 , or C—C 6 H 11 .
- Scheme 9 shows a method of synthesis to compound Ia.
- R is 5 t-butyl, isopropyl, adamantyl, (1,1)-dimethylpropane, (1,1-diethylbutane), c-C 5 H 9 , or c-C 6 H 11 , and Ms is mesylate.
- One method includes reacting (+/ ⁇ )-tert-butyl-methyl-phosphane borane as a starting material.
- This primary phosphine is made via a one-pot procedure starting from dichloromethylphosphine, reacting with dimethylsulfide-borane, t-butyl magnesium chloride, and then LAH.
- (+/ ⁇ )-tert-butyl-methyl-phosphane borane is reacted with a chiral auxiliary that includes K 2 CO 3 , DMSO, and N-chloroacetyl-(S)-( ⁇ )-4-benzyl-2-oxazolidinone at 55° C.
- Each diastereomer can then be reduced with NaBH 4 to remove the chiral auxiliary and form either enantiomer of the alcohol, 2-(tert-butyl-methyl-phosphanyl)-ethanol, as shown in Scheme 9.
- the alcohol is then reacted with mesylate chloride and pyridine to form the compound IX.
- the corresponding enantiomer of compound IX can also be formed by choosing the opposite diastereomer.
- Compound IX can then be reacted with a mixture of n-butyl lithium and compound VII.
- compound IX can then be reacted with a mixture of n-butyl lithium and t-butylmethylphosphine borane to form Bis-P and a meso product.
- the compound with the general Formula IIa can be synthesized via the route shown in Scheme 10, wherein R is t-butyl, isopropyl, adamantyl, (1,1)-dimethylpropane, (1,1-diethylbutane), c-C 5 H 9 , or c-C 6 H 11 ; and Ms is mesylate.
- the compound with the general Formula Ib can be synthesized via the route shown in Scheme 11, wherein R is t-butyl, isopropyl, adamantyl, (1,1)-dimethylpropane, (1,1-diethylbutane), c-C 5 H 9 , or c-C 6 H 11 .
- Another compound can be synthesized via the route shown in Scheme 12. wherein R is t-butyl, isopropyl, adamantyl, (1,1)-dimethylpropane, (1,1-diethylbutane), c-C 5 H 9 , or c-C 6 H 11 ; and Ms is mesylate.
- Conditions can be used for borane removal or deprotection from the phosphorous atom of borane protected ligands, such as compounds shown in Scheme 9, that do not lead to racemization at the non-C 2 -symmetric center to form compounds I, Ia, lb, Ic, and Ia.
- the borane group can be removed by treating the phosphine borane ligand with HBF 4 .Me 2 O followed by hydrolysis with K 2 CO 3 .
- the borane groups can be removed from an intermediate ligand to form a compound with the formula Ia.
- ligands of the general formulas I can be bound immediately to rhodium by reacting the ligand with [Rh(norbornadiene)BF 4 ] 2 to yield a catalyst with the Formula XIa:
- the achiral phosphorous group includes at least one achiral phosphorous atom having one bond to each of two identical atoms other than the bridge;
- the chiral phosphorous group comprises at least one phosphorous atom, wherein the at least one phosphorous atom is chiral or the at least one phosphorous atom is bonded to a chiral substituent;
- a Bridge is a —(CH 2 ) n — where n is an integer from 1 to 12; a 1,2-divalent phenyl: or a 1,2-divalent substituted phenyl.
- any suitable transition metal, actinide, or lanthanide and corresponding anion can be used to form the metal/non-C 2 bisphosphine complex shown as compound XI.
- the corresponding anion can alternatively be PF 6 —, SbF 6 —, Otf ⁇ , or ClO 4 ⁇ .
- Scheme 9 Also shown in Scheme 9 is a synthesis method for the formation of BisP. Either enantiomer of compound IX can then easily be converted to either enantiomer of BisP, or the ligand Ia, as shown in Scheme 9.
- the difference in the synthesis of BisP and the ligand Ia is the use of either di-t-butylphosphine borane in the synthesis of ligand Ia or t-butylmethylphosphine borane in the synthesis of BisP, as the nucleophile that displaces the mesylate in the last step of the synthesis.
- nucleophilic displacement creates yet another chiral center resulting in a reaction mixture that contains a 50:50 mixture of the chiral ligand and the meso ligand.
- the meso compound is easily separated from the chiral compound by column chromatography.
- no further chiral centers are formed in the reaction so all of the material in the reaction mixture after addition is a single enantiomer chiral compound, Ia.
- Metal/non-C 2 -symmetric ligands of the general Formula XI can be used to catalyze hydrogenation and other asymmetric reactions.
- compounds of the general Formula XI can also be used as catalysts in transformations including, but not limited to, hydroformylation, t-allyl palladium coupling, hydrosilation, hydrocyanation, olefin metathesis, hydroacylation, and isomerization of allylamines.
- the metal/non-C 2 -symmetric phospholanes can catalyze various substrates.
- a complex represented by the Formula XIa a complex represented by the Formula XIa,
- R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C 5 H 9 , or c-C 6 H 11 , can be used to catalyze substrates, such as enamides, enol esters, and succinates, with the general structural formula
- X is N, O, or C;
- R 1 is an alkyl, a carboxylic acid derivative, a carboxylic ester, or a nitrile;
- R 2 is an alkyl, an acetyl derivative, or a carboxylic acid;
- R 3 is an alkyl or hydrogen, and
- R 4 is an alkyl identical to the alkyl in R 3 or hydrogen.
- Metal/non-C 2 -symmetric compounds typically bond to a substrate to be catalyzed through the center, M, which is bound to a phosphorous atom of the chiral and achiral phosphorous groups, of a compound with the structural Formula XIb, its corresponding enantiomer, or solvates thereof
- R is an alkyl, fluoroalkyl, or perfluoroalkyl group each containing up to about 8 carbon atoms, an aryl group, a substituted aryl group, an aralkyl group, or a ring substituted aralkyl group;
- a Bridge is a —(CH 2 ) n — where n is an integer from 1 to 12; a 1,2-divalent phenyl; or a 1,2-divalent substituted phenyl; and
- M is a transition metal, an actinide, or a lanthanide.
- a solvate of the Formula XIb includes compounds having one or more solvent molecules bonded to the M center.
- the solvent molecules include, but are not limited to, MeOH, THF, ethanol, isopropanol, acetonitrile, methylene chloride, benzene, toluene, water, ethyl acetate, dioxane, carbon tetrachloride, DMSO, DMF, DMF/water mixtures, supercritical carbon dioxide, alcohol/water mixtures or any other suitable solvent.
- THF was distilled from sodium prior to use or THF (anhydrous, 99.9%) was used as needed from Aldrich Sure-Seal bottles supplied by Aldrich Chemical Company.
- Dichloromethane anhydrous, 99.8%
- diethyl ether anhydrous, 99.8%
- Methyl sulfoxide DMSO, A.C.S.
- the acquisition window was typically 8000 Hz from +18 to ⁇ 2 ppm (Reference TMS @ 0 ppm), and processing was with 0.2 Hz line broadening.
- Typical acquisition time is 80 seconds.
- Regular 13 C NMR spectra were acquired using 45-degree tip angle pulses, 2.0 second recycle delay, and 2048 scans at a resolution of 1 Hz/point.
- Spectral width was typically 25 KHz from +235 to ⁇ 15 ppm (Reference TMS @ 0 ppm).
- Proton decoupling was applied continuously, and 2 Hz line broadening was applied during processing.
- Typical acquisition time is 102 minutes.
- 31 P NMR spectra were acquired using 45-degree tip angle pulses, 1.0 second recycle delay, and 64 scans at a resolution of 2 Hz/point.
- Spectral width was typically 48 KHz from +200 to ⁇ 100 ppm (Reference 85% Phosphoric Acid @ 0 ppm).
- Proton decoupling was applied continuously, and 2 Hz line broadening was applied during processing. Typical acquisition time is 1.5 minutes.
- High Performance Liquid Chromatography High Performance Liquid Chromatography (HPLC) was performed on a series 1100 Hewlett Packard (now Agilent Technologies) instrument equipped with a manual injector, quaternary pump, and a UV detector. The LC was PC controlled using HP Chemstation Plus Software. Reverse phase HPLC was performed with a 150 ⁇ 4.6 mm BDS-Hypersil-C18 column supplied by Keystone Scientific Incorporated. Reverse phase chiral HPLC was performed using a Chiracel OJ-R column supplied by Chiral Technologies. Normal Phase chiral HPLC was performed a Chiracel OD-H column supplied by Chiral Technologies.
- PCl 3 (3.94 g, 2.5 mL, 0.029 mole) was dissolved in 75 mL anhydrous THF in a 250-mL round bottom flask under N 2 and then cooled to 0° C. with an ice bath.
- the tert-butylmagnesium chloride (29 mL, 0.058 mole, 2.0 M in diethyl ether) was added dropwise via syringe, and then the reaction was stirred 1.5 hours at 0° C.
- Lithium aluminum hydride (1.1 g, 0.029 mole) was then delivered to the reaction as a dry powder in portions over 20 minutes.
- borane methylsulfide (2.9 m]L, 0.029 mole 10.0 M solution) was delivered via syringe. After stirring overnight, the reaction was cooled to 0° C. and then quenched cautiously with 150 mL 1N HCl. The reaction mixture was poured into a separatory funnel, and the organic layer was separated. The aqueous layer was extracted with 2 ⁇ 100 mL Et 2 O and then the combined organics were dried over MgSO 4 . The volatiles were then removed on a rotary evaporator at reduced pressure. The crude product was passed through a plug of silica gel using 3% ethyl acetate/hexane to yield the title compound with sufficient purity for subsequent chemistry.
- tert-butylmagnesium chloride (107 mL, 0.214 mole, 2.0 M in ethyl ether) was delivered via the addition funnel over a period of one hour while maintaining the reaction solution at 0° C. During the addition, a white precipitate formed which persisted during stirring for 45 minutes after the addition. Lithium aluminum hydride was then delivered to the reaction as a dry powder in portions over 20 minutes while maintaining the reaction temperature at 0° C. After the addition the reaction was warmed to room temperature and then stirred overnight. It was then cooled to 0° C. and quenched cautiously with 400 mL 1N HCl. The organic layer was separated, and then the aqueous layer was extracted with 100 mL Et 2 O.
- N-Chloroacetyl-(S)-( ⁇ )-4-benzyl-2-oxazolidinone (6.39 g, 0.0254 mole) was placed in a 250-mL round bottom flask. (+/ ⁇ )-tert-butyl-methyl-phosphane borane was added to the flask along with 75 mL DMSO. Potassium carbonate (17.5 g, 0.127 mole) was added in one portion and the reaction was placed under N 2 . The reaction was heated to 55° C. in an oil bath and stirred for one hour. The resulting solution was red and K 2 CO 3 was not completely dissolved in solution.
- the reaction was cooled to room temperature and then was poured into 500 mL 1N HCl which had been chilled to 0° C. Ethyl acetate (300 mL) was added and the biphasic solution was shaken briskly in a separatory funnel. The organic layer was separated and then the aqueous layer was extracted with 100 mL ethyl acetate. The combined organic layers were then washed successively with distilled water and then brine. The organic layer was dried over MgSO 4 and the solvent was removed in vacuo.
- the crude white oily product was triturated with 2 ⁇ 75 mL warm hexane to remove excess phosphine and then the resulting white solid was dissolved in 30 mL hot ethyl acetate and allowed to cool to room temperature. Upon cooling, crystals formed. The crystals were collected on filter paper and then washed with 30 mL hexane. Crystals then formed in the filtrate. The diastereomeric ratio of the crystals on the filter paper was 92 ((S,R) isomer):8 ((S,S) isomer) and they weighed 1.17 g.
- the organic layer was separated after shaking and then the aqueous layer was extracted with 2 ⁇ 50 mL ethyl acetate. The organic layers were combined and dried over MgSO 4 and then the volatiles were removed invacuo. The crude product was passed through a plug of silica gel using 25% ethyl acetate/hexane and after removing the volatiles in vacuo, 1.651 g/97.1% of the title compound was isolated.
- the (S) isomer can be synthesized via the same procedure starting from (S)-4-benzyl-3-[2-((S)-tert-butyl-methyl-phosphanyl)-ethanoyl]-oxazolidin-2-one.
- the (S) isomer can be synthesized via the same procedure starting from (S)-2-(tert-butyl-methyl-phosphanyl)-ethanol.
- Methanesulfonic acid 2-((R)-tert-butyl-methyl-phosphanyl borane)-ethyl ester (536 mg, 2.232 mmole) was dissolved in 7 mL anhydrous THF in a 50-mL round bottom flask under N 2 . The solution was cooled to ⁇ 78° C. with a dry ice/acetone bath with stirring. In a separate 25-mL round bottom flask was dissolved (+/ ⁇ )-tert-butyl-methyl-phosphane borane. This solution was placed under N 2 and then cooled to ⁇ 78° C.
- n-BuLi (1.07 mL, 2.678 mmole, 2.5 M in hexane) was added dropwise via syringe to the (+/ ⁇ )-tert-butyl-methyl-phosphane borane solution.
- the reaction was stirred for 20 minutes at ⁇ 78° C. and then the solution was taken up in a syringe and delivered to the mesylate solution over 30 seconds.
- the reaction was stirred 20 minutes at ⁇ 78° C. and then warmed to room temperature and stirred overnight.
- the (S,S) isomer can be synthesized via the same procedure starting from Methanesulfonic acid 2-((S)-tert-butyl-methyl-phosphanyl borane)-ethyl ester.
- Enantiomeric purity was determined by chiral HPLC using a Chiracel OD-H column (10 mm, 4.6 ⁇ 250 mm), mobile phase Hexanes:IPA:TFA 95:5:0.1, flow rate of 0.5 mL/min, and RI detection at 1/16 range.
- the (S,S) isomer was observed at 17.9 minutes and the (R,R) isomer was observed at 12.0 minutes.
- Spectral data was identical to that described in Imamoto T., et al., supra., 1998.
- Methanesulfonic acid 2-((R)-tert-butyl-methyl-phosphanyl borane)-ethyl ester (660 mg, 2.75 mmole) was dissolved in 7 mL anhydrous THF in a 50-mL round bottom flask under N 2 . The solution was cooled to ⁇ 78° C. with a dry ice/acetone bath. In a separate 25-mL round bottom flask was dissolved di-tert-butyl-phosphane borane (528 mg, 3.30 mmole). This solution was placed under N 2 and then cooled to ⁇ 78° C.
- n-BuLi (1.32 mL, 3.30 mmole, 2.5 M in hexane) was added dropwise via syringe to the di-tert-butyl-phosphane borane solution.
- the reaction was stirred for 20 minutes at ⁇ 78° C. and then the solution was taken up in a syringe and delivered to the mesylate solution over 30 seconds.
- the reaction was stirred 20 minutes at ⁇ 78° C. and then warmed to room temperature and stirred overnight.
- the (S) isomer can be synthesized via the same procedure starting from Methanesulfonic acid 2-((S)-tert-butyl-methyl-phosphanyl borane)-ethyl ester.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Health & Medical Sciences (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Catalysts (AREA)
Abstract
Non-C2-symmetric bisphospholane ligands and methods for their preparation are described. Use of metal/non-C2-symmetric bisphospholane complexes to catalyze asymmetric transformation reactions to provide high enantiomeric excesses of formed compounds is also described.
Description
- This invention relates to non-C2-symmetric bisphosphine (BisP) ligands and a method for their preparation. In addition, this invention relates to forming metal/bisphosphine complexes that catalyze asymmetric transformation reactions to generate high enantiomeric excesses of formed compounds. The invention also relates to a method for preparing BisP.
- A growing trend in the pharmaceutical industry is to market chiral drugs in enantiomerically pure form to provide desired positive effects in humans. Production of enantiomerically pure compounds is important for several reasons. First, one enantiomer often provides a desired biological function through interactions with natural binding sites, but another enantiomer typically does not have the same function or effect. Further, it is possible that one enantiomer has harmful side effects, while another enantiomer provides a desired positive biological activity. To meet this demand for chiral drugs, many approaches for obtaining enantiomerically pure compounds have been explored such as diastereomeric resolution, structural modification of naturally occurring chiral compounds, asymmetric catalysis using synthetic chiral catalysts and enzymes, and the separation of enantiomers using simulated moving bed (SMB) technology.
- Asymmetric catalysis is often the most efficient method for the synthesis of enantiomerically enriched compounds because a small amount of a chiral catalyst can be used to produce a large quantity of a chiral target molecule. Over the last two decades, more than a half-dozen commercial industrial processes have been developed that use asymmetric catalysis as the key step in the production of enantiomerically pure compounds with a tremendous effort focused on developing new asymmetric catalysts for these reactions (Morrison J. D., ed.Asymmetric Synthesis, New York: Academic Press, 1985:5; Bosnich B., ed. Asymmetric Catalysis, Dordrecht, Netherlands: Martinus Nijhoff Publishers, 1986; Brunner H. Synthesis, 1988:645; Noyori R., Kitamura M. In Scheffold R., ed. Modern Synthetic Methods, Berlin Hedelberg: Springer-Verlag, 1989;5:115; Nugent W. A., RajanBabu T. V., Burk M. J. Science, 1993;259:479; Ojima I., ed. Catalvtic Asymnmetric Synthesis, New York: VCH, 1993; Noyori R. Asynmmetric Catalysis In Organic Synthesis, New York: John Wiley & Sons, Inc, 1994).
- Chiral phosphine ligands have played a significant role in the development of novel transition metal catalyzed asymmetric reactions to produce enantiomeric excess of compounds with desired activities. The first successful attempts at asymmetric hydrogenation of enamide substrates were accomplished in the late 1970s using chiral bisphosphines as transition metal ligands (Vineyard B. D., Knowles W. S., Sabacky M. J., Bachman G. L., Weinkauff D. J.J. Am. Chem. Soc. 1977;99(18):5946-52; Knowles W. S., Sabacky M. J., Vineyard B. D., Weinkauff D. J. J. Am. Chem. Soc. 1975;97(9):2567-8).
- Since these first published reports, there has been an explosion of research geared toward the synthesis of new chiral bisphosphine ligands for asymmetric hydrogenations and other chiral catalytic transformations (Ojima I., ed.Catalytic Asyiniietric Synthesis, New York: VCH Publishers, Inc, 1993; Ager D. J., ed. Handbook of Chiral Chemicals, Marcel Dekker, Inc, 1999). Highly selective rigid chiral phospholane ligands have been used to facilitate these asymmetric reactions. For example, phospholane ligands are used in the asymmetric hydrogenation of enamide substrates and other chiral catalytic transformations.
- BPE, Duphos, and BisP ligands are some of the most efficient and broadly useful ligands developed for asymmetric hydrogenation to date (Burk M. J.Chemtracts 1998; 11(11):787-802 (CODEN: CHEMFW ISSN: 1431-9268. CAN 130:38423; AN 1998:698087 CAPLUS); Burk M. J., Bienewald F., Harris M., Zanotti-Gerosa A. Angew Chew., Int. Ed. 1998;37(13/14):1931-1933; Burk, M. J., Casy G., Johnson N. B. J. Org. Chem. 1998;63(18):6084-6085; Burk M. J., Kalberg C. S., Pizzano A. J. Am. Chem. Soc. 1998;120(18):43454353; Burk M. J., Harper T., Gregory P., Kalberg C. S. J. Am. Chem. Soc. 1995; 117(15):4423-4424; Burk M. J., Feaster J. E., Nugent W. A., Harlow R. L. J. Am. Chem. Soc. 1993;115(22):10125-10138; Nugent W. A., RajanBabu T. V., Burk M. J. Science (Washington, D.C. 1883-) 1993;259(5094):479-483; Burk M. J., Feaster J. E., Harlow R. L. Tetrahedron: Asymmetry 1991;2(7):569-592; Burk M J. J. Am. Chem. Soc. 1991;113(22):8518-8519; Imamoto T., Watanabe J., Wada Y., Masuda H., Yamada H., Tsuruta H. et al. J. Am. Chem. Soc. 1998; 120(7):1635-1636; Zhu G, Cao P, Jiang Q, Zhang X. J. Am. Chem. Soc. 1997;119(7):1799-1800). For example, a Rhodium/Duphos complex can be used to selectively form (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid, known as pregabalin, which is used as an anti-seizure drug. The S-enantiomer, which is produced in an enantiomeric excess, is preferred because it shows better anticonvulsant activity than the R-enantiomer (Yuen et al., Bioorganic & Medicinal Chemistry Letters 1994;4:823).
- The success of BPE, DuPhos, and BisP transition metal complexes in asymmetric hydrogenations is derived from many factors. For example, substrate to catalyst ratios of up to 50,000/1 have been demonstrated. Also, high rates of substrate conversion to product using low hydrogen pressures have been observed with catalysts made from these ligands.
-
- This structural feature creates areas of hindrance in the BisP/metal complexes and produces desired stereochemical results in asymmetric hydrogenation reactions. However, there are a variety of reactions in which only modest enantioselectivity has been achieved with these ligands. While high selectivity has been observed in many reactions using these chiral diphosphine ligands, there are many reactions where these ligands are not very efficient in terms of activity and selectivity. Further, there are many disadvantages associated with these ligands, which limits their application.
- For example, multiple chiral centers in these ligands increases the difficulty in synthesis of these compounds. Further, the multiple chiral centers could increase the cost associated with forming the ligands.
- High enantioselectivities have been observed in asymmetric hydrogenation for a narrow range of substrates, such as enamides, enol esters, and succinates. Many of these successful results have been obtained using optically pure C2-symmetric rhodium-phosphine complexes as hydrogenation catalysts. Therefore, C2-symmetry has become a popular characteristic in the design of chiral ligands that are used to make these complexes. Unique to the substrates for which asymmetric hydrogenation has been successful is an olefin and a carbonyl group which are separated by one atom. During asymmetric hydrogenation, the olefin and the carbonyl bind to the metal center in a well-defined conformation. This is thought to be of consequence in an asymmetric hydrogenation.
-
- A proton from one of the methyl groups of t-butyldimethyl phosphine is selectively deprotonated with a chiral base, such as s-BuLi and (−)-sparteine, and then the resulting anion couples with itself in the presence of copper(II) chloride to provide the bisphosphine borane protected ligand, in about 40% yield and >99% enantiomeric excess after recrystallization. The rhodium complex of BisP is known to give high enantiomeric excess in hydrogenation reactions for a variety of substrates. For instance, the rhodium-BisP catalyst hydrogenates α-N-acetylmethylacrylate to produce 98% enantiomeric excess (Imamoto T. et al., supra., 1998).
- A drawback to the synthesis of the BisP ligand in Scheme 2 is that only one antipode of sparteine is available in nature, and therefore, only one enantiomer of the ligand (the S,S isomer) can be synthesized via this route.
- Basic research has been done by a variety of groups in the late 1970s on the mechanism and origin of enantioselectivity of asymmetric hydrogenation reactions which result in high enantiomeric excess (Alcock N. W., Brown J. M.; Derome A. E., Lucy A. R.J. Chem. Soc. Chem. Comm. 1985:575; Brown J. M., Chaloner P. A., Morris G. A. J. Chem. Soc. Chem. Comm. 1983:664; Halpern J. Science 1982;217,401; Brown J. M., Chaloner P. A. J. Client. Soc. Chem. Comm. 1980;344). The 3-dimensional structure of a C2-symmetric complex like the rhodium complex of BisP has four quadrants that alternate hindered and unhindered, as shown in Scheme 1.
- Ligand and metal/ligand complexes are needed that can further improve the production of enantiomerically active forms of compounds. Thus, there is a need to develop methods for the production of and to synthesize compounds that reduce the number of chiral centers on a molecule and through prohibitive substituents on the ligand improve enantioselectivity in asymmetric reactions.
-
- wherein:
- the achiral phosphorous group includes at least one achiral phosphorous atom having one bond to each of two identical atoms other than the bridge;
- the chiral phosphorous group comprises at least one phosphorous atom, wherein the at least one phosphorous atom is chiral or the at least one phosphorous atom is bonded to a chiral substituent; and
- the Bridge is a —(CH2)n— where n is an integer from 1 to 12; a 1,2-divalent phenyl; or a 1,2-divalent substituted phenyl.
-
- wherein:
- the achiral phosphorous group includes at least one achiral phosphorous atom having one bond to each of two identical atoms other than the bridge;
- the chiral phosphorous group comprises at least one phosphorous atom, wherein the at least one phosphorous atom is chiral or the at least one phosphorous atom is bonded to a chiral substituent; and
- each Y is independently halogen, alkyl, alkoxy, aryl, aryloxy, nitro, amino, vinyl, substituted vinyl, alkynyl, or sulfonic acid, and n is an integer from 0 to 4 equal to the number of unsubstituted aromatic ring carbons.
-
- wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane) c-C5H9, or c-C6H11; and Ms is mesylate.
- Another aspect of the invention is directed to methods for forming non-C2-bisphosphine ligands. The methods include preparing compounds of the general structural Formulas I and II, as shown in Schemes 4-12.
-
- wherein:
- the achiral phosphorous group includes at least one achiral phosphorous atom having one bond to each of two identical atoms other than the bridge;
- the chiral phosphorous group comprises at least one phosphorous atom, wherein the at least one phosphorous atom is chiral or the at least one phosphorous atom is bonded to a chiral substituent;
- a Bridge is a —(CH2)n— where n is an integer from 1 to 12; a 1,2-divalent phenyl; or a 1,2-divalent substituted phenyl;
- M is a transition metal, an actinide, or a lanthanide; and
- Z is BF4, PF6, SbF6, OTf, or ClO4.
- Yet another aspect of the invention is directed to forming enantiomeric excesses of compounds catalyzed with the metal/non-C2-symmetric bisphosphine complexes in asymmetric reactions.
- The present invention is applicable to the synthesis of non-Co-symmetric bisphosphine ligands for use in metal/non-C2-symmetric bisphosphine complexes for asymmetric catalysis. In particular, the present invention is directed to reacting the metal/non-C2-symmetric bisphosphine complexes to produce enantiomeric excesses of compound in asymmetric hydrogenation syntheses. While the present invention is not so limited, an appreciation of various aspects of the invention will be gained through a discussion of the examples provided below.
- For the purpose of this application, the “corresponding enantiomer” means that if a compound includes a stereochemical configuration designated as R, the corresponding enantiomer is the S configuration. If a compound has an S configuration, the corresponding enantiomer is the R configuration. If a compound has a stereochemical configuration of 1R,2S, the “corresponding enantiomer” is the 1S,2R compound. Similarly, if a compound has an 1S,2R configuration, the “corresponding enantiomer” is the 1R,2S compound. If a P-chiral compound has an 1S,2S configuration, the “corresponding enantiomer” is the 1R,2R compound. If a compound has an 1R,2R configuration, the “corresponding enantiomer” is the 1S,2S compound.
- For the purpose of this application, a high level of enantioselectivity means a hydrogenation that yields a product of greater than or equal to about 80%, preferably, greater than or equal to about 90% enantiomeric excess (abbreviated e.e.).
- Enantiomeric excess is defined as the ratio (% R−% S)/(% R+% S)×100, where % R is the percentage of R enantiomer and % S is the percentage of S enantiomer in a sample of optically active compound. For the purpose of this application, by a “compound with a high degree of enantiomeric purity,” or a “compound of high enantiomeric purity” is meant a compound that exhibits enantiomeric excess to the extent of greater than or equal to about 90%, preferably, greater than or equal to about 95% enantiomeric excess (abbreviated e.e.).
- Non-C2-Symmetric Bisphosphines
-
- wherein:
- the achiral phosphorous group includes at least one achiral phosphorous atom having one bond to each of two identical atoms other than the bridge;
- the chiral phosphorous group comprises at least one phosphorous atom, wherein the at least one phosphorous atom is chiral or the at least one phosphorous atom is bonded to a chiral substituent; and
- the Bridge is a —(CH2)n— where n is an integer from 1 to 12; a 1,2-divalent phenyl; or a 1,2-divalent substituted phenyl.
-
- wherein:
- the achiral phosphorous group includes at least one achiral phosphorous atom having one bond to each of two identical atoms other than the bridge;
- the chiral phosphorous group comprises at least one phosphorous atom, wherein the at least one phosphorous atom is chiral or the at least one phosphorous atom is bonded to a chiral substituent; and
- each Y is independently halogen, alkyl, alkoxy, aryl, aryloxy, nitro, amino, vinyl, substituted vinyl, alkynyl, or sulfonic acid, and n is an integer from 0 to 4 equal to the number of unsubstituted aromatic ring carbons.
- The term “alkyl”, as used in this application, includes a straight or branched saturated aliphatic hydrocarbon chain, such as, for example, methyl, ethyl, propyl, isopropyl (1-methylethyl), butyl, tert-butyl (1,1-dimethylethyl), and the like.
- The term “aryl” group, as used in this application, includes an aromatic hydrocarbon group, including fused aromatic rings, such as, for example phenyl and naphthyl. Such groups may be unsubstituted or substituted on the aromatic ring by, for example, an alkoxy group of 1 to 4 carbon atoms, an amino group, a hydroxy group, or an acetyloxy group.
- The term “aralkyl” group, as used in this application, includes an aromatic hydrocarbon group, including fused aromatic rings, such as for example, phenyl and naphthyl, bonded to an alkyl group with the alkyl bonded to the phospholane ring. The aromatic hydrocarbon group may be unsubstituted or substituted (ring substituted aralkyl) by, for example, an alkoxy group of 1 to 4 carbon atoms, an amino group, a hydroxy group, or an acetyloxy group.
- The term “LAH,” as used in this application, is defined as lithium aluminum hydride.
-
- wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or c-C6H11.
-
- wherein:
- R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or C—C6H11;
- R2 is methyl, ethyl, isopropyl, cyclohexyl, benzyl, a ring substituted benzyl, an aryl, or a ring substituted aryl; and
- R3 is OBn, OH, sulphonate, or hydrogen.
- A preferred R group for the achiral phosphorous groups of compounds of the general Formula I is t-butyl. Examples of other preferred non-C2-symmetric bisphosphine ligands of the general Formula I include, but are not limited to, those compounds in which R is isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or c-C6H11 and their corresponding enantiomers.
-
- wherein R is t-butyl. In other embodiments, R is isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or c-C6H11.
-
- wherein R is t-butyl.
-
- wherein R is t-butyl, and R2 is alkyl.
-
- wherein R is t-butyl, and R2 is alkyl.
- Compounds of the general Formulas Ia, Ib, and Ic include the corresponding enantiomer of the compound shown in the structural formulas.
- The bisphosphine compounds of Formula I and II of the present invention are useful as transition metal ligands in asymmetric catalysis. The use of these ligands to form transition metal catalysts results in a high level of enantioselective and stereochemical control in the catalyzed hydrogenation of unsaturated substrates.
- Compounds I and II include one to three chiral centers instead of the four chiral centers that are found in molecules such as Duphos. Ligands displaying the structural motif of Ia do not necessarily have to contain bulky groups on phosphorous that are the same. In other words, as long as there are three sterically hindered quadrants in the metal-ligand complex, the desired effect in asymmetric transformations will be achieved.
-
- wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or c-C6H11; and Ms is mesylate.
- The above bisphospholane compounds of Formulas I, II, and their corresponding enantiomers can be complexed with any of the transition metals as well as the lanthanides and actinides. Such complexes are formed by methods known in the art. Another compound of the present invention includes the metal/P-chiral phospholane complex with the general structural Formula VIII and its corresponding enantiomer:
- wherein:
- the achiral phosphorous group includes at least one achiral phosphorous atom having one bond to each of two identical atoms other than the bridge;
- the chiral phosphorous group comprises at least one phosphorous atom, wherein the at least one phosphorous atom is chiral or the at least one phosphorous atom is bonded to a chiral substituent;
- a Bridge is a —(CH2)n— where n is an integer from 1 to 12; a 1,2-divalent phenyl; or a 1,2-divalent substituted phenyl;
- M is a transition metal, an actinide, or a lanthanide; and
- Z is BF4, PF6, SbF6, OTf, or ClO4.
- Preferred transition metal complexes of the present invention are those including the above described preferred compounds complexed with rhodium.
- Synthesis of non-C7 Bisphosphines
-
-
-
-
-
-
-
-
- One method includes reacting (+/−)-tert-butyl-methyl-phosphane borane as a starting material. This primary phosphine is made via a one-pot procedure starting from dichloromethylphosphine, reacting with dimethylsulfide-borane, t-butyl magnesium chloride, and then LAH. (+/−)-tert-butyl-methyl-phosphane borane is reacted with a chiral auxiliary that includes K2CO3, DMSO, and N-chloroacetyl-(S)-(−)-4-benzyl-2-oxazolidinone at 55° C. to form a mixture of diastereomers (S)-4-benzyl-3-[2-((R)-tert-butyl-methyl-phosphanyl)-ethanoyl]-oxazolidin-2-one and (S)-4-benzyl-3-[2-((S)-tert-butyl-methyl-phosphanyl)-ethanoyl]-oxazolidin-2-one in quantitative yield. These diastereomers can be separated either by column chromatography or via recrystallization.
- Each diastereomer can then be reduced with NaBH4 to remove the chiral auxiliary and form either enantiomer of the alcohol, 2-(tert-butyl-methyl-phosphanyl)-ethanol, as shown in Scheme 9. The alcohol is then reacted with mesylate chloride and pyridine to form the compound IX. The corresponding enantiomer of compound IX can also be formed by choosing the opposite diastereomer. Compound IX can then be reacted with a mixture of n-butyl lithium and compound VII. Alternatively, compound IX can then be reacted with a mixture of n-butyl lithium and t-butylmethylphosphine borane to form Bis-P and a meso product.
-
-
-
-
-
- wherein:
- the achiral phosphorous group includes at least one achiral phosphorous atom having one bond to each of two identical atoms other than the bridge;
- the chiral phosphorous group comprises at least one phosphorous atom, wherein the at least one phosphorous atom is chiral or the at least one phosphorous atom is bonded to a chiral substituent; and
- a Bridge is a —(CH2)n— where n is an integer from 1 to 12; a 1,2-divalent phenyl: or a 1,2-divalent substituted phenyl.
- Any suitable transition metal, actinide, or lanthanide and corresponding anion can be used to form the metal/non-C2 bisphosphine complex shown as compound XI. For example, the corresponding anion can alternatively be PF6—, SbF6—, Otf−, or ClO4 −.
- Synthesis Route to BisP
- Also shown in Scheme 9 is a synthesis method for the formation of BisP. Either enantiomer of compound IX can then easily be converted to either enantiomer of BisP, or the ligand Ia, as shown in Scheme 9. The difference in the synthesis of BisP and the ligand Ia is the use of either di-t-butylphosphine borane in the synthesis of ligand Ia or t-butylmethylphosphine borane in the synthesis of BisP, as the nucleophile that displaces the mesylate in the last step of the synthesis. In the synthesis of BisP, nucleophilic displacement creates yet another chiral center resulting in a reaction mixture that contains a 50:50 mixture of the chiral ligand and the meso ligand. The meso compound is easily separated from the chiral compound by column chromatography. In the case of the di-tert-butylphosphine borane addition, no further chiral centers are formed in the reaction so all of the material in the reaction mixture after addition is a single enantiomer chiral compound, Ia.
- Asymmetric Transformations with Metal/Non-C2-Symmetric Ligands
- Metal/non-C2-symmetric ligands of the general Formula XI can be used to catalyze hydrogenation and other asymmetric reactions. For example, compounds of the general Formula XI can also be used as catalysts in transformations including, but not limited to, hydroformylation, t-allyl palladium coupling, hydrosilation, hydrocyanation, olefin metathesis, hydroacylation, and isomerization of allylamines.
- In the case of asymmetric hydrogenation reactions, the metal/non-C2-symmetric phospholanes can catalyze various substrates. For example, a complex represented by the Formula XIa,
-
-
-
- wherein X is N, O, or C; R1 is an alkyl, a carboxylic acid derivative, a carboxylic ester, or a nitrile; R2 is an alkyl, an acetyl derivative, or a carboxylic acid; and R3 is an alkyl or hydrogen, and R4 is an alkyl identical to the alkyl in R3 or hydrogen.
-
- wherein:
- R is an alkyl, fluoroalkyl, or perfluoroalkyl group each containing up to about 8 carbon atoms, an aryl group, a substituted aryl group, an aralkyl group, or a ring substituted aralkyl group;
- a Bridge is a —(CH2)n— where n is an integer from 1 to 12; a 1,2-divalent phenyl; or a 1,2-divalent substituted phenyl; and
- M is a transition metal, an actinide, or a lanthanide.
- A solvate of the Formula XIb includes compounds having one or more solvent molecules bonded to the M center. The solvent molecules include, but are not limited to, MeOH, THF, ethanol, isopropanol, acetonitrile, methylene chloride, benzene, toluene, water, ethyl acetate, dioxane, carbon tetrachloride, DMSO, DMF, DMF/water mixtures, supercritical carbon dioxide, alcohol/water mixtures or any other suitable solvent.
- Materials. THF was distilled from sodium prior to use or THF (anhydrous, 99.9%) was used as needed from Aldrich Sure-Seal bottles supplied by Aldrich Chemical Company. Dichloromethane (anhydrous, 99.8%) and diethyl ether (anhydrous, 99.8%) were used as needed from Aldrich Sure-Seal bottles supplied by Aldrich Chemical Company. Methyl sulfoxide (DMSO, A.C.S. reagent, 99.9%), sodium borohydride (995), methanesulfonyl chloride (99.5%+), tert-butylmagnesium chloride (2.0 M diethyl ether), borane-methylsulfide complex (approximately 10-10.2 M), phosphorous trichloride (98%), lithium aluminum hydride (powder, 95%), and n-BuLi (2.5M hexanes) were obtained from Aldrich Chemical Company. N-chloroacetyl-(S)-(−)-4-benzyl-2-oxazolidinone was prepared according to literature procedures described in Tang, J. S., Verkade J. G.J. Org. Chem. 1996;61:8750-8754.
- Nuclear Magnetic Resonance. 400 MHz1H NMR, 100 MHz 13C NMR, and 162 MHz 31P NMR spectra were obtained on “Barton”—a Varian Unity+400 (Inova40O after Aug. 15, 2000) spectrometer equipped with an Auto Switchable 4-Nuclei PFG probe, two RF channels, and a SMS-100 sample changer by Zymark. Spectra were generally acquired near room temperature (21° C.), and standard autolock, autoshim, and autogain routines were employed. Samples are usually spun at 20 Hz for ID experiments. 1H NMR spectra were acquired using 45-degree tip angle pulses, 1.0 second recycle delay, and 16 scans at a resolution of 0.25 Hz/point. The acquisition window was typically 8000 Hz from +18 to −2 ppm (Reference TMS @ 0 ppm), and processing was with 0.2 Hz line broadening. Typical acquisition time is 80 seconds. Regular 13C NMR spectra were acquired using 45-degree tip angle pulses, 2.0 second recycle delay, and 2048 scans at a resolution of 1 Hz/point. Spectral width was typically 25 KHz from +235 to −15 ppm (Reference TMS @ 0 ppm). Proton decoupling was applied continuously, and 2 Hz line broadening was applied during processing. Typical acquisition time is 102 minutes. 31P NMR spectra were acquired using 45-degree tip angle pulses, 1.0 second recycle delay, and 64 scans at a resolution of 2 Hz/point. Spectral width was typically 48 KHz from +200 to −100 ppm (Reference 85% Phosphoric Acid @ 0 ppm). Proton decoupling was applied continuously, and 2 Hz line broadening was applied during processing. Typical acquisition time is 1.5 minutes.
- High Performance Liquid Chromatography. High Performance Liquid Chromatography (HPLC) was performed on a series 1100 Hewlett Packard (now Agilent Technologies) instrument equipped with a manual injector, quaternary pump, and a UV detector. The LC was PC controlled using HP Chemstation Plus Software. Reverse phase HPLC was performed with a 150×4.6 mm BDS-Hypersil-C18 column supplied by Keystone Scientific Incorporated. Reverse phase chiral HPLC was performed using a Chiracel OJ-R column supplied by Chiral Technologies. Normal Phase chiral HPLC was performed a Chiracel OD-H column supplied by Chiral Technologies.
- Synthesis of di-tert-butyl-phosphane borane
- PCl3 (3.94 g, 2.5 mL, 0.029 mole) was dissolved in 75 mL anhydrous THF in a 250-mL round bottom flask under N2 and then cooled to 0° C. with an ice bath. The tert-butylmagnesium chloride (29 mL, 0.058 mole, 2.0 M in diethyl ether) was added dropwise via syringe, and then the reaction was stirred 1.5 hours at 0° C. Lithium aluminum hydride (1.1 g, 0.029 mole) was then delivered to the reaction as a dry powder in portions over 20 minutes. After the addition, borane methylsulfide (2.9 m]L, 0.029 mole 10.0 M solution) was delivered via syringe. After stirring overnight, the reaction was cooled to 0° C. and then quenched cautiously with 150 mL 1N HCl. The reaction mixture was poured into a separatory funnel, and the organic layer was separated. The aqueous layer was extracted with 2×100 mL Et2O and then the combined organics were dried over MgSO4. The volatiles were then removed on a rotary evaporator at reduced pressure. The crude product was passed through a plug of silica gel using 3% ethyl acetate/hexane to yield the title compound with sufficient purity for subsequent chemistry. 1H NMR (400 MHz, CDCl3) δ 0.0-0.9 (m, 3H), 1.28 (d, JH-P=13.4 Hz, 18H), 3.65 (dm, JH-P=351.2 Hz, 1H); 31P NMR (162 MHz, CDCl3) δ 49.0 ppm (br m).
- Synthesis of tert-butyl-methyl-phosphane Borane
- Dichloromethylphosphine (25 g, 0.214 mole) was poured out of an ampule into a 3-neck 1000-mL flask equipped with an addition funnel while blowing N2 through the flask. Nitrogen degassed anhydrous Et2O (350 mL) was immediately poured into the flask and then the flask was sealed with a septum. The solution was cooled to 0° C. and then borane methylsulfide (21.4 mL, 0.214 moles, 10.0 M solution) was delivered to the solution via syringe. After stirring for 20 minutes, tert-butylmagnesium chloride (107 mL, 0.214 mole, 2.0 M in ethyl ether) was delivered via the addition funnel over a period of one hour while maintaining the reaction solution at 0° C. During the addition, a white precipitate formed which persisted during stirring for 45 minutes after the addition. Lithium aluminum hydride was then delivered to the reaction as a dry powder in portions over 20 minutes while maintaining the reaction temperature at 0° C. After the addition the reaction was warmed to room temperature and then stirred overnight. It was then cooled to 0° C. and quenched cautiously with 400 mL 1N HCl. The organic layer was separated, and then the aqueous layer was extracted with 100 mL Et2O. The combined organics were combined and washed with 1N HCl and brine and then dried over MgSO4. Removal of the solvent in vacuo yielded 23.4 g/93% of the title compound with sufficient purity for subsequent chemistry. 1H NMR (400 MHz, CDCl3) δ 0-0.8 (m, 3H), 1.17 (d, JH-P=14.65 Hz, 9H), 1.28 (dd, J=4.64 Hz, J=5.86 Hz, 3H), 4.38 (dm, JH-P=355.2 Hz, 1H); 31P NMR (162 MHz, CDCl3) δ 12.0 (br m).
- Synthesis of (S)-4-Benzyl-3-[2-((R)-tert-butyl-methyl-phosphanyl)-ethanoyl]-oxazolidin-2-one and (S)-4-Benzyl-3-[2-((S)-tert-butyl-methyl-phosphanyl)-ethanoyl]-oxazolidin-2-one
- N-Chloroacetyl-(S)-(−)-4-benzyl-2-oxazolidinone (6.39 g, 0.0254 mole) was placed in a 250-mL round bottom flask. (+/−)-tert-butyl-methyl-phosphane borane was added to the flask along with 75 mL DMSO. Potassium carbonate (17.5 g, 0.127 mole) was added in one portion and the reaction was placed under N2. The reaction was heated to 55° C. in an oil bath and stirred for one hour. The resulting solution was red and K2CO3 was not completely dissolved in solution. The reaction was cooled to room temperature and then was poured into 500 mL 1N HCl which had been chilled to 0° C. Ethyl acetate (300 mL) was added and the biphasic solution was shaken briskly in a separatory funnel. The organic layer was separated and then the aqueous layer was extracted with 100 mL ethyl acetate. The combined organic layers were then washed successively with distilled water and then brine. The organic layer was dried over MgSO4 and the solvent was removed in vacuo. The crude white oily product was triturated with 2×75 mL warm hexane to remove excess phosphine and then the resulting white solid was dissolved in 30 mL hot ethyl acetate and allowed to cool to room temperature. Upon cooling, crystals formed. The crystals were collected on filter paper and then washed with 30 mL hexane. Crystals then formed in the filtrate. The diastereomeric ratio of the crystals on the filter paper was 92 ((S,R) isomer):8 ((S,S) isomer) and they weighed 1.17 g. After collecting the crystals from the filtrate on filter paper and washing with hexane it was found that the diastereomeric ratio of these crystals was 8 ((S,R) isomer):92 ((S,S) isomer) and then weighed 1.20 g. Successive recrystallization of both diastereomers with EtOAc/hexane yielded compounds with diastereomeric purity exceeding 99%. It is also possible to separate the (S,R) and (S,S) diastereomers via column chromatography over silica gel (15% ethyl acetate, hexane) collecting the (S,R) isomer at Rf=0.38 and the (S,S) isomer at Rf=0.28. Stereochemistry of the chirogenic phosphorous atom of each diastereomer was assigned by analogy using a comparison of elution orders of the enantiomers of Bis-P boranes made from this route with the elution orders of Bis-P boranes described in Imamoto, T. et al., supra., 1998.
- (S)-4-Benzyl-3-[2-((R)-tert-butyl-meth yl-phosphanyl)-ethanoyl]-oxazolidin-2-one
-
- (S)4-Benzyl-3-[2-((S)-tert-butyl-methyl-phosphanyl)-ethanoyl]-oxazolidin-2-one:
-
- Synthesis of (R)-2-(tert-butyl-methyl-phosphanyl)-ethanol
- (S)-4-Benzyl-3-[2-((R)-tert-butyl-methyl-phosphanyl)-ethanoyl]-oxazolidin-2-one was dissolved in 60 mL anhydrous THF and then cooled to 0° C. in a 250-mL round bottom flask. NaBH4 was added in one portion along with 15 mL distilled water. The reaction foamed after addition and when foaming was complete the reaction was warmed to room temperature and stirred overnight whereupon the reaction was quenched with 50 mL 2N HCl. The reaction was poured into a separatory funnel and 30 mL ethyl acetate was added. The organic layer was separated after shaking and then the aqueous layer was extracted with 2×50 mL ethyl acetate. The organic layers were combined and dried over MgSO4 and then the volatiles were removed invacuo. The crude product was passed through a plug of silica gel using 25% ethyl acetate/hexane and after removing the volatiles in vacuo, 1.651 g/97.1% of the title compound was isolated. The (S) isomer can be synthesized via the same procedure starting from (S)-4-benzyl-3-[2-((S)-tert-butyl-methyl-phosphanyl)-ethanoyl]-oxazolidin-2-one. 1H NMR (400 MHz, CDCl3) δ 1.14 (d, JH-P=13.74 Hz, 9H), 1.25 (d, JH-P=9.9 Hz, 3H), 1.81-1.92 (m, 2H), 2.42 (br s, 1H); 3.92 (dt, J=15.2 Hz, J=6.3 Hz, 2H); 13C (100 MHz, CDCl3) δ6.3 (d, JC-P=35.1 Hz), 24.6 (d, J=32.1 Hz), 24.9, 27.2 (d, JC-P=35.1 Hz), 57.8; 31P (162 MHz, CDCl3) δ 23.2 (br m).
- Synthesis of Methanesulfonic Acid 2-((R)-tert-butyl-methyl-phosphanyl Borane)-ethyl Ester
- The (R)-2-(tert-butyl-methyl-phosphanyl)-ethanol (1.127 g, 6.957 mmole) was dissolved in 10 mL pyridine and cooled to 0° C. Methanesulfonyl chloride (0.59 mL, 7.65 mmole) was added dropwise via syringe. After one hour white salts had precipitated from the reaction solution. The reaction was then quenched with 50 mL distilled water. The reaction mixture was poured into a separatory funnel and the aqueous layer was extracted with 2×50 mL Et2O. The combined organics were dried over MgSO4 and then the volatiles were removed in vacuo yielding 1.553 g/93% of the mesylate product which was subjected to no further purification. The (S) isomer can be synthesized via the same procedure starting from (S)-2-(tert-butyl-methyl-phosphanyl)-ethanol. 1H NMR (400 MHz, CDCl3) δ 0.0-0.8 (br m), 1.17 (d, JH-P=14.2 Hz, 9H), 1.30 (d, JH-P=9.9 Hz, 3H), 1.90 (br s, 1H), 2.08 (dt, J=10.9 Hz, J=7.5 Hz, 2H), 3.05 (s, 3H), 4.41-4.59 (m, 2H); 31P NMR (162 MHz, CDCl3) δ 25.5 (br m).
- Synthesis of (R,R)-1,2-Bis(tert-butyl-methyl-phosphanyl Borane) Ethane
- Methanesulfonic acid 2-((R)-tert-butyl-methyl-phosphanyl borane)-ethyl ester (536 mg, 2.232 mmole) was dissolved in 7 mL anhydrous THF in a 50-mL round bottom flask under N2. The solution was cooled to −78° C. with a dry ice/acetone bath with stirring. In a separate 25-mL round bottom flask was dissolved (+/−)-tert-butyl-methyl-phosphane borane. This solution was placed under N2 and then cooled to −78° C. n-BuLi (1.07 mL, 2.678 mmole, 2.5 M in hexane) was added dropwise via syringe to the (+/−)-tert-butyl-methyl-phosphane borane solution. The reaction was stirred for 20 minutes at −78° C. and then the solution was taken up in a syringe and delivered to the mesylate solution over 30 seconds. The reaction was stirred 20 minutes at −78° C. and then warmed to room temperature and stirred overnight. TLC (25% ethyl acetate/hexane) showed two products with Rf=0.49 (meso Bis-P) and Rf=0.38 (Bis-P). Column chromatography over silica gel-eluting first with 7% ethyl acetate/hexane and increasing the gradient eventually to 25% ethyl acetate/hexane yielded 130 mg/44.5% meso compound and 147 mg/50.3% Bis-P (>99% e.e. of the (R,R) isomer). The (S,S) isomer can be synthesized via the same procedure starting from Methanesulfonic acid 2-((S)-tert-butyl-methyl-phosphanyl borane)-ethyl ester. Enantiomeric purity was determined by chiral HPLC using a Chiracel OD-H column (10 mm, 4.6×250 mm), mobile phase Hexanes:IPA:TFA 95:5:0.1, flow rate of 0.5 mL/min, and RI detection at 1/16 range. The (S,S) isomer was observed at 17.9 minutes and the (R,R) isomer was observed at 12.0 minutes. Spectral data was identical to that described in Imamoto T., et al., supra., 1998.
- Synthesis of 1-(Di-tert-butyl-phosphanyl Borane)-((R)-2-tert-butyl-methyl-phosphanyl Borane) Ethane
- Methanesulfonic acid 2-((R)-tert-butyl-methyl-phosphanyl borane)-ethyl ester (660 mg, 2.75 mmole) was dissolved in 7 mL anhydrous THF in a 50-mL round bottom flask under N2. The solution was cooled to −78° C. with a dry ice/acetone bath. In a separate 25-mL round bottom flask was dissolved di-tert-butyl-phosphane borane (528 mg, 3.30 mmole). This solution was placed under N2 and then cooled to −78° C. n-BuLi (1.32 mL, 3.30 mmole, 2.5 M in hexane) was added dropwise via syringe to the di-tert-butyl-phosphane borane solution. The reaction was stirred for 20 minutes at −78° C. and then the solution was taken up in a syringe and delivered to the mesylate solution over 30 seconds. The reaction was stirred 20 minutes at −78° C. and then warmed to room temperature and stirred overnight. TLC (25% ethyl acetate/hexane) showed title product with Rf=0.53. Column chromatography over silica gel (10% ethyl acetate/hexane) yielded 370 mg/44% of the title compound. The (S) isomer can be synthesized via the same procedure starting from Methanesulfonic acid 2-((S)-tert-butyl-methyl-phosphanyl borane)-ethyl ester. 1H NMR (400 MHz, CDCl3) δ -0.2-0.8 (br m, 3H), 1.05-1.30 (br m, 30H), 1.50-1.70 (br m, 2H), 1.75-2.05 (br m, 2H); 31P NMR (162 MHz, CDCl3) δ 30.0 (br m), 47.0 (br, m).
- It should be noted that, as used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to a composition containing “a compound” includes a mixture of two or more compounds.
- The present invention should not be considered limited to the particular examples described above, but rather should be understood to cover all aspects of the invention as fairly set out in the attached claims. Various modifications, equivalent processes, as well as numerous structures to which the present invention may be applicable will be readily apparent to those of skill in the art to which the present invention is directed upon review of the instant specification.
Claims (32)
1. A non-C2 bisphosphine ligand of the structural formula:
wherein the achiral phosphorous group includes at least one achiral phosphorous atom having at least two bonds to atoms other than the bridge;
the chiral phosphorous group comprises at least one phosphorous atom, wherein the at least one phosphorous atom is chiral or the at least one phosphorous atom is bonded to a chiral substituent; and
the Bridge is a —(CH2)n— where n is an integer from 1 to 12; a 1,2-divalent phenyl; or a 1,2-divalent substituted phenyl.
3. The ligand according to claim 1 , wherein the chiral phosphorous group is
4. The ligand according to claim 1 which is 1-(di-tert-butyl-phosphanyl borane)-((R)-2-tert-butyl-methyl-phosphanyl borane) ethane.
5. The ligand according to claim 1 which is 1-((S)-2,2′-phosphanyl-1,1′-binaphthyl)-2-((R)-2-tert-butyl-methyl-phosphanyl) ethane.
6. The ligand according to claim 1 which is 1-((R)-2-tert-butyl-methyl-phosphanyl)-2-((R,R)—),5-dialkylphosphanyl) ethane.
10. A non-C2 bisphosphine ligand of the structural formula:
wherein:
the achiral phosphorous group includes at least one achiral phosphorous atom having at least two bonds to atoms other than the bridge;
the chiral phosphorous group comprises at least one phosphorous atom, wherein the least one phosphorous atom is chiral or the at least one phosphorous atom is bonded to a chiral substituent; and
each Y is independently halogen, alkyl, alkoxy, aryl, aryloxy, nitro, amino, vinyl, substituted vinyl, alkynyl, or sulfonic acid and n is an integer from 0 to 4 equal to the number of unsubstituted aromatic ring carbons.
12. The ligand according to claim 10 , wherein the chiral phosphorous group is
wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or c-C6H11;
R2 is methyl, ethyl, isopropyl, cyclohexyl, benzyl, a ring substituted benzyl, an aryl, or a ring substituted aryl; and
R3 is OBn, OH, sulphonate, or hydrogen; or
its corresponding enantiomer.
13. The ligand according to claim 10 which is 1-((R)-2-tert-butyl-methyl-phosphanyl)-2-((R,R)-2,5-dialkylphosphanyl) benzene.
14. A catalyst of the structural formula:
wherein:
the achiral phosphorous group includes at least one achiral phosphorous atom having at least two bonds to atoms other than the bridge;
the chiral phosphorous group comprises at least one phosphorous atom, wherein the at least one phosphorous atom is chiral or the at least one phosphorous atom is bonded to a chiral substituent;
a Bridge is a —(CH2)n— where n is an integer from 1 to 12; a 1,2-divalent phenyl; or a 1,2-divalent substituted phenyl;
M is a transition metal, an actinide, or a lanthanide; and
Z is BF4, PF6, SbF6, OTf, or ClO4; or
its corresponding enantiomer.
15. The catalyst of claim 14 , wherein M is rhodium.
16. A method for forming a ligand with the structural formula
wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or c-C6H11; and
R2 is an alkyl, cyclohexyl, benzyl, or phenyl;
comprising the step of reacting a compound of the formula
wherein R2 is an alkyl, benzyl, or phenyl, in the presence of s-BuLi and THF with a second compound of the formula
wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or c-C6H11; and Ms is mesylate.
17. A method for forming a ligand with the structural formula
wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or c-C6H11; and
R9 is an alkyl or benzyl;
comprising the step of reacting a compound of the formula
wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or c-C6H11, in the presence of n-BuLi and THF, with a second compound selection from the group consisting of
wherein R2 is an alkyl or cyclohexyl; and Ms is mesylate.
18. A method for forming a ligand with the structural formula
wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or c-C6H11;
comprising the step of reacting a compound of the formula
wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or c-C6H11, in the presence of n-BuLi and THF, with a second compound of the formula
19. A method for forming a ligand with the structural formula
wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or C—C6HI 1; and
R2 is an alkyl or benzyl;
comprising the step of reacting a compound of the formula
wherein R2 is an alkyl or benzyl, in the presence of s-BuLi and THF with a second compound of the formula
wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or c-C6H11.
20. A method for forming a ligand with the structural formula
wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or c-C6H11; and
R2 is an alkyl or benzyl;
comprising the step of reacting a compound of the formula
wherein R2 is an alkyl or benzyl, in the presence of s-BuLi and THF with a second compound of the formula
wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or c-C6H11.
21. A method for forming a ligand with the structural formula
wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), C—C5H9, or C—C6H11;
comprising the step of reacting a compound of the formula
in the presence of s-BuLi and THF with a second compound of the formula
wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or c-C6H11.
22. A method for forming a ligand with the structural formula
or its corresponding enantiomer, wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or c-C6H11, and Ms is mesylate, comprising the steps of:
(a) reacting a compound of the formula
wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or c-C6H11, in the presence of K2CO3 and DMSO with a second compound of the formula
or its corresponding enantiomer, wherein R′ is methyl, benzyl, aryl, or isopropyl and R″ is hydrogen, methyl, benzyl, aryl, or isopropyl, forming a first intermediate having the structural formula
or its corresponding enantiomer, wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or c-C6H11;
(b) reacting the frist intermediate with NaBH4 and water in the presence of THF, forming a second intermediate of the formula
wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or c-C6H11; and
(c) reacting the second intermediate in the presence of pyridine with MsCl.
23. A method for forming a ligand with the structural formula
or its corresponding enantiomer, wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or c-C6H11;
comprising the step of reacting a compound of the formula
wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or c-C6H11 and Ms is mesylate in the presence of n-BuLi with a second compound of the formula
wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or c-C6H11.
25. A method for forming a chiral ligand of the structural formula or the corresponding enantiomer
wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or c-C6H1; and R1 is alkyl;
comprising the steps of
(a) reacting 1,2-dibromobenzene in the presence of tetra-triphenyl phosphene palladium and triethyl-amine with phosphonic acid diethyl ester forming (2-bromo-phenyl)-phosphonic acid diethyl ester;
(b) reacting (2-bromo-phenyl)-phosphonic acid diethyl ester with lithium aluminum hydride forming 2-bromo-phenyl-phosphane;
(c) reacting 2-bromo-phenyl-phosphane in the presence of n-BuLi with a compound of the structural formula
wherein R1 is alkyl to form an intermediate having the structural formula
wherein R1 is alkyl; and
(d) reacting the intermediate in the presence of t-BuLi with a second compound having the structural formula
wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or c-C6H11.
26. A method for forming a chiral ligand of the structural formula or the corresponding enantiomer
wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or c-C6H11;
comprising the steps of
(a) reacting 2-bromo-phenyl-phosphane in the presence of n-BuLi with 2,2′-bis-chloromethyl-[1,1′]binaphthalenyl forming (2-bromo-phenyl)-methyl-(2′-methyl-[1,1′]binaphthalenyl-2-ylmethyl)-phosphane; and
(b) reacting (2-bromo-phenyl)-methyl-(2′-methyl-[1,1′]binaphthalenyl-2-ylmethyl)-phosphane in the presence of t-BuLi with a compound having the structural formula
wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or c-C6H11.
27. A method for forming a chiral ligand of the structural formula or the corresponding enantiomer
wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or c-C6H11; and R1 is alkyl;
comprising the steps of
(a) reacting 2-bromo-phenyl-phosphane in the presence of n-BuLi with a compound of the structural formula
wherein R1 is alkyl to form an intermediate having the structural formula
wherein R1 is alkyl; and
(b) reacting the intermediate in the presence of t-BuLi with a second compound having the structural formula
wherein R is t-butyl, isopropyl, adamantyl, (1,1-dimethylpropane), (1,1-diethylbutane), c-C5H9, or c-C6H11.
28. A method for an asymmetric transformation comprising the step of reacting a substrate with general structural formula
wherein X is N, O, or C; R1 is an alkyl, a carboxylic acid derivative, a carboxylic ester, or a nitrile; R2 is an alkyl, an acetyl derivative, or a carboxylic acid; R3 is an alkyl or hydrogen; and R4 is the R3 alkyl or hydrogen;
with a compound of the structural formula, the corresponding enantiomer, or a solvate thereof
wherein:
the achiral phosphorous group includes at least one achiral phosphorous atom having at least two bonds to atoms other than the bridge;
the chiral phosphorous group comprises at least one phosphorous atom, wherein the at least one phosphorous atom is chiral or the at least one phosphorous atom is bonded to a chiral substituent; and
a Bridge is a —(CH2)n— where n is an integer from 1 to 12; a 1,2-divalent phenyl; or a 1,2-divalent substituted phenyl;
M is a transition metal; an actinide; or a lanthanide;
or its corresponding enantiomer, or a solvate thereof.
29. The method of claim 28 , wherein M is rhodium.
30. The method of claim 28 , wherein the asymmetric transformation is a hydrogenation reaction.
31. The method of claim 28 , wherein the substrate is 3-cyano-5-methylhex-3-enoic acid.
32. The method of claim 28 , wherein a product of the asymmetric transformation has a high degree of enantiomeric excess.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/741,117 US20040138487A1 (en) | 2001-03-19 | 2003-12-19 | Synthesis of non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27712501P | 2001-03-19 | 2001-03-19 | |
US10/083,923 US6689915B2 (en) | 2001-03-19 | 2002-02-27 | Synthesis of non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation |
US10/741,117 US20040138487A1 (en) | 2001-03-19 | 2003-12-19 | Synthesis of non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/083,923 Division US6689915B2 (en) | 2001-03-19 | 2002-02-27 | Synthesis of non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040138487A1 true US20040138487A1 (en) | 2004-07-15 |
Family
ID=23059501
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/083,923 Expired - Fee Related US6689915B2 (en) | 2001-03-19 | 2002-02-27 | Synthesis of non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation |
US10/245,941 Expired - Fee Related US6855849B2 (en) | 2001-03-19 | 2002-09-18 | Non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation |
US10/741,117 Abandoned US20040138487A1 (en) | 2001-03-19 | 2003-12-19 | Synthesis of non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation |
US11/039,611 Expired - Fee Related US7414156B2 (en) | 2001-03-19 | 2005-01-20 | Non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/083,923 Expired - Fee Related US6689915B2 (en) | 2001-03-19 | 2002-02-27 | Synthesis of non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation |
US10/245,941 Expired - Fee Related US6855849B2 (en) | 2001-03-19 | 2002-09-18 | Non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/039,611 Expired - Fee Related US7414156B2 (en) | 2001-03-19 | 2005-01-20 | Non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation |
Country Status (6)
Country | Link |
---|---|
US (4) | US6689915B2 (en) |
EP (1) | EP1243591A3 (en) |
JP (1) | JP3888677B2 (en) |
BR (1) | BR0200846A (en) |
CA (1) | CA2377069C (en) |
MX (1) | MXPA02001147A (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE41920E1 (en) | 1996-07-24 | 2010-11-09 | Warner-Lambert Company Llc | Isobutylgaba and its derivatives for the treatment of pain |
MXPA02001147A (en) | 2001-03-19 | 2004-04-21 | Warner Lambert Co | Synthesis of non-c2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation. |
JP4005801B2 (en) * | 2001-12-10 | 2007-11-14 | 高砂香料工業株式会社 | Novel phosphine ligand |
US20040072680A1 (en) * | 2002-04-26 | 2004-04-15 | The Penn State Research Foundation | Chiral phosphorus cyclic compounds for transition metal-catalyzed asymmetric reactions |
US7265242B2 (en) * | 2004-02-26 | 2007-09-04 | Shell Oil Company | Process for the carbonylation of ethylenically or acetylenically unsaturated compounds |
EP1735263A1 (en) * | 2004-02-26 | 2006-12-27 | Shell Internationale Researchmaatschappij B.V. | Process for the carbonylation of ethylenically or acetylenically unsaturated compounds |
KR100847922B1 (en) * | 2004-03-12 | 2008-07-22 | 워너-램버트 캄파니 엘엘씨 | C1-symmetric bisphosphine ligands and their use in the asymmetric synthesis of pregabalin |
EP1843988B1 (en) * | 2004-12-23 | 2013-02-13 | Superconductor Technologies, Inc. | Rf-properties-optimized compositions of (re)ba2cu3o7-d thin film superconductors |
ES2403066T3 (en) | 2005-04-08 | 2013-05-13 | Dsm Ip Assets B.V. | Lactone Preparation |
WO2006108636A1 (en) | 2005-04-15 | 2006-10-19 | Dsm Ip Assets B.V. | Manufacture of thiolactones |
WO2007091445A1 (en) * | 2006-02-08 | 2007-08-16 | Japan Science And Technology Agency | Bis(phosphine)boronium salts, process for preparation of bis(phosphine)boronium salts, and bis(phosphine)boronium salts prepared by the process |
WO2007091446A1 (en) * | 2006-02-08 | 2007-08-16 | Japan Science And Technology Agency | Method for producing diphosphine compound, diphosphine compound produced by such production method, and intermediate product |
EP1864990A1 (en) * | 2006-06-01 | 2007-12-12 | Universität Wien | Preparation of secondary phosphines |
US7547577B2 (en) * | 2006-11-14 | 2009-06-16 | Endicott Interconnect Technologies, Inc. | Method of making circuitized substrate with solder paste connections |
JP2008189633A (en) * | 2007-02-08 | 2008-08-21 | Nippon Chem Ind Co Ltd | Method for producing optically active dialkylphosphinomethane derivative |
EP2116618A1 (en) | 2008-05-09 | 2009-11-11 | Agency for Science, Technology And Research | Diagnosis and treatment of Kawasaki disease |
GB0812297D0 (en) * | 2008-07-04 | 2008-08-13 | Lucite Int Uk Ltd | Novel carbonylation ligand sand thier use of in the carbonylation of ethylenically unsaturated compounds |
JP5378837B2 (en) * | 2009-03-11 | 2013-12-25 | 日本化学工業株式会社 | Process for producing optically active bisphosphinomethane |
CN105188926B (en) | 2013-03-11 | 2018-01-09 | 新泽西鲁特格斯州立大学 | Organometallic catalytic for asymmetric transformation |
CN108409784B (en) * | 2017-02-09 | 2020-07-14 | 上海交通大学 | Preparation method of phosphorus chiral important intermediate |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4606636A (en) * | 1983-10-25 | 1986-08-19 | Universite De Saint-Etienne | Optical apparatus for identifying the individual multiparametric properties of particles or bodies in a continuous flow |
US5646241A (en) * | 1995-05-12 | 1997-07-08 | Quantum Materials, Inc. | Bleed resistant cyanate ester-containing compositions |
US5741412A (en) * | 1993-06-03 | 1998-04-21 | University Of Alberta | Multiple capillary biochemical analyzer |
US6103083A (en) * | 1998-02-20 | 2000-08-15 | Tetragen | Capillary electrophoresis apparatus and method |
US6194593B1 (en) * | 2000-01-28 | 2001-02-27 | Nippon Chemical Industrial Co., Ltd. | 1, 2-bis(dialkylphosphino) benzene derivates having optical activites, process for producing same, and rhodium metal complexes containing same as ligands |
US6376715B1 (en) * | 1998-03-16 | 2002-04-23 | Ineos Acrylics U.K. Limited | Process for the preparation of bisphosphines |
US6387235B1 (en) * | 1998-09-09 | 2002-05-14 | Hitachi, Ltd. | Apparatus for the separation and fractionation of differentially expressed gene fragments |
US20020080349A1 (en) * | 2000-12-22 | 2002-06-27 | Armstrong Thomas M. | Sample chamber for use in analytical instrumentation |
US20020123073A1 (en) * | 2001-01-26 | 2002-09-05 | Varouj Amirkhanian | Multi-channel bio-separation cartridge |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4028625B2 (en) | 1997-09-11 | 2007-12-26 | 小川香料株式会社 | Phosphine compounds and rhodium complexes using them as ligands |
DE19824121A1 (en) | 1998-05-29 | 1999-12-02 | Basf Ag | Production of optically active phospholanes, their metal complexes and use in asymmetric synthesis |
CA2340943A1 (en) | 1998-08-21 | 2000-03-02 | The Penn State Research Foundation | Asymmetric catalysis based on chiral phospholanes |
JP2972887B1 (en) | 1998-10-29 | 1999-11-08 | 千葉大学長 | Asymmetric synthesis using optically active bisphosphinomethanes and their rhodium or copper complexes |
GB9823716D0 (en) | 1998-10-29 | 1998-12-23 | Isis Innovation | Diphosphines |
JP4290265B2 (en) | 1999-03-02 | 2009-07-01 | 第一ファインケミカル株式会社 | Novel asymmetric ligand |
JP4201916B2 (en) | 1999-05-10 | 2008-12-24 | 日本化学工業株式会社 | Optically active 1,2-bis (dialkylphosphino) benzene derivative, process for producing the same, and rhodium metal complex having the compound as a ligand |
MXPA02001147A (en) | 2001-03-19 | 2004-04-21 | Warner Lambert Co | Synthesis of non-c2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation. |
-
2002
- 2002-01-31 MX MXPA02001147A patent/MXPA02001147A/en active IP Right Grant
- 2002-02-27 US US10/083,923 patent/US6689915B2/en not_active Expired - Fee Related
- 2002-03-12 EP EP02005577A patent/EP1243591A3/en not_active Withdrawn
- 2002-03-15 CA CA002377069A patent/CA2377069C/en not_active Expired - Fee Related
- 2002-03-18 JP JP2002074577A patent/JP3888677B2/en not_active Expired - Fee Related
- 2002-03-18 BR BR0200846-7A patent/BR0200846A/en not_active IP Right Cessation
- 2002-09-18 US US10/245,941 patent/US6855849B2/en not_active Expired - Fee Related
-
2003
- 2003-12-19 US US10/741,117 patent/US20040138487A1/en not_active Abandoned
-
2005
- 2005-01-20 US US11/039,611 patent/US7414156B2/en not_active Expired - Fee Related
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4606636A (en) * | 1983-10-25 | 1986-08-19 | Universite De Saint-Etienne | Optical apparatus for identifying the individual multiparametric properties of particles or bodies in a continuous flow |
US5741412A (en) * | 1993-06-03 | 1998-04-21 | University Of Alberta | Multiple capillary biochemical analyzer |
US5646241A (en) * | 1995-05-12 | 1997-07-08 | Quantum Materials, Inc. | Bleed resistant cyanate ester-containing compositions |
US6103083A (en) * | 1998-02-20 | 2000-08-15 | Tetragen | Capillary electrophoresis apparatus and method |
US6376715B1 (en) * | 1998-03-16 | 2002-04-23 | Ineos Acrylics U.K. Limited | Process for the preparation of bisphosphines |
US6387235B1 (en) * | 1998-09-09 | 2002-05-14 | Hitachi, Ltd. | Apparatus for the separation and fractionation of differentially expressed gene fragments |
US6194593B1 (en) * | 2000-01-28 | 2001-02-27 | Nippon Chemical Industrial Co., Ltd. | 1, 2-bis(dialkylphosphino) benzene derivates having optical activites, process for producing same, and rhodium metal complexes containing same as ligands |
US20020080349A1 (en) * | 2000-12-22 | 2002-06-27 | Armstrong Thomas M. | Sample chamber for use in analytical instrumentation |
US20020123073A1 (en) * | 2001-01-26 | 2002-09-05 | Varouj Amirkhanian | Multi-channel bio-separation cartridge |
Also Published As
Publication number | Publication date |
---|---|
JP3888677B2 (en) | 2007-03-07 |
CA2377069A1 (en) | 2002-09-19 |
JP2002338586A (en) | 2002-11-27 |
EP1243591A2 (en) | 2002-09-25 |
US7414156B2 (en) | 2008-08-19 |
US20050124830A1 (en) | 2005-06-09 |
US20020143214A1 (en) | 2002-10-03 |
MXPA02001147A (en) | 2004-04-21 |
US6855849B2 (en) | 2005-02-15 |
BR0200846A (en) | 2003-03-25 |
EP1243591A3 (en) | 2003-07-02 |
CA2377069C (en) | 2007-08-07 |
US20030073868A1 (en) | 2003-04-17 |
US6689915B2 (en) | 2004-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7414156B2 (en) | Non-C2-symmetric bisphosphine ligands as catalysts for asymmetric hydrogenation | |
Kolodiazhnyi | Recent developments in the asymmetric synthesis of Р-chiral phosphorus compounds | |
Darcel et al. | Direct use of chiral or achiral organophosphorus boranes as pro-ligands for transition metal catalyzed reactions | |
US6399787B1 (en) | Catalytic asymmetric hydrogenation, hydroformylation, and hydrovinylation via transition metal catalysts with phosphines and phosphites | |
C. Córdoba et al. | Palladium Complexes of Methylene-Bridged P-Stereogenic, Unsymmetrical Diphosphines | |
US6750171B2 (en) | Synthesis of P-chiral bisphospholane ligands and their transition metal complexes for use as asymmetric hydrogenation catalysts | |
CA2380566C (en) | Novel chiral phosphorus ligands and the use thereof in the production of optically active products | |
US6207868B1 (en) | Asymmetric synthesis catalyzed by transition metal complexes with chiral ligands | |
JP2004091488A (en) | Method for production of phosphite and transition metal complex | |
CA2287713A1 (en) | Optically active bisphosphinomethanes and their rhodium and copper complexes for catalytic asymmetric syntheses | |
EP1030854B1 (en) | Catalysts for asymmetric synthesis containing rigid chiral ligands | |
Jaillet et al. | P (III)-Chirogenic Phosphinite Building Blocks by Stereospecific N→ O Phosphinyl Migration | |
WO2006082054A1 (en) | 1,4-bis-diphosphines, 1,4-bis-diphosphites and 1,4-bis- diphosphonites from optically active (z)-olefines as chiral ligands | |
Cheow | Asymmetric ligand transformation reactions promoted by cyclometallated complexes | |
Maienza | P-stereogenic ligands in rhodium-and ruthenium-catalyzed asymmetric hydrogenation | |
Liu | Asymmetric synthesis of chiral phosphines and arsines promoted by organometallic complexes | |
Zou | Synthesis of New Phosphorus Ligands for Asymmetric Catalysis | |
Liu | Ligand development for transition metal catalyzed reactions | |
Wu | Synthesis of novel chiral dipyridylphosphine ligands and their application in catalytic asymmetric hydrogenation reactions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |